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Abstract
p53 is an intrinsically disordered transcription factor that suppresses tumor
development by arresting the cell cycle and promoting DNA repair. p53 deletions or mutations
can lead to cancer due to the inability of cells to respond to stress. The protein levels and
post-translational modification state of p53 changes in response to cellular stress like DNA
damage. Previous studies have shown that p53 can undergo coupled folding and binding with
the E3 ubiquitin ligase, Mdm2, and the histone deacetylase, p300. In normal cells, p53 is kept
at a low level by Mdm2, which marks it with ubiquitin, targeting p53 for proteasome
degradation. In turn, p53 activates the transcription of Mdm2. This negative feedback loop
not only regulates p53 levels but also the fate of the cell. In stressful conditions, such as
DNA damage, p53 levels increase within the nucleus, where it becomes active and
induces cell growth arrest or apoptosis.
p53 consists of discrete domains that participate in sequence-specific DNA
binding, tetramerization, and transcriptional activation. p53 contains two transactivation
domains (TAD1 and TAD2), that contain multiple phosphorylation sites. The disordered
p53 transactivation domain (p53TAD) contains specific levels of transient helical
secondary structure that are necessary for its binding to the negative regulators, Mdm2
and MdmX. The interactions of p53 with Mdm2 and MdmX are also modulated by
posttranslational modifications (PTMs) of p53TAD including phosphorylation at S15, T18
and S20 that inhibits p53-Mdm2 binding. It is unclear whether the levels of transient
secondary structure in p53TAD are changed by phosphorylation or other PTMs. We used
vi

phosphomimetic mutants to determine if adding a negative charge at positions 15 and 18
has any effect on the transient secondary structure of p53TAD and protein-protein
binding. Using a combination of biophysical and structural methods, we investigated the
effects of single and multisite phosphomimetic mutations on the transient secondary
structure of p53TAD and its interaction with Mdm2, MdmX, and the KIX domain. The
phosphomimetics reduced Mdm2 and MdmX binding affinity by 3-5-fold, but resulted in
minimal changes in transient secondary structure, suggesting that the destabilizing effect
of phosphorylation on the p53TAD-Mdm2/MdmX interaction is primarily electrostatic.
Phosphomimetics had no effect on the p53-KIX interaction, suggesting that increased
binding of phosphorylated p53 to KIX may be influenced by decreased competition with
p53 negative regulators.
Previous studies have shown that there is an intramolecular interaction between
p53TAD and the DNA binding domain of p53 and that this interaction can reduce
sequence-specific DNA binding. We aim to determine whether mutations within TAD2
combined with site-specific phosphorylation can decrease p53-DNA binding. Two
consecutive hydrophobic residues within TAD2 (W53, F54), which are surrounded by
acidic amino acids, are essential for the activity of the transactivation domain. We will
determine the effect that these mutated sites have on DNA binding. Using biophysical
methods, we investigated the effects of point mutations and phosphomimetic mutations
on the interaction between p53 and DNA. Our binding data shows that phosphomimicry
of the p53TAD decreases DNA binding affinity, while substituting the hydrophobic
residues, (W53, F54), with acidic residues within TAD2 of p53 increases DNA binding. By
determining the impact that phosphorylation has on the binding affinity of p53 we will

vii

identify a new understanding of the structure and function of not just p53 but other
intrinsically disordered proteins.
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Chapter One: Introduction of intrinsically disordered proteins
General characteristics
Many proteins are classified as ordered proteins, capable of forming stable
secondary, tertiary and even quaternary structures. These proteins have adopted these
complex folded structures in order to perform cellular functions. In the past two decades,
a group of proteins have emerged that do not have these following characteristics. These
proteins, called intrinsically disordered proteins (IDP), are highly dynamic and lack a fixed
or ordered structure. They form specific heterogeneous conformational ensembles that
fluctuate over time [6-10]. IDPs are structurally very different from ordered proteins and
tend to have distinct properties in terms of function, sequence, interactions, evolution and
regulation [9, 11, 12]. A polypeptide’s function is determined by its amino acid sequence.
The composition of amino acid residues in ordered proteins varies greatly from that of
disordered proteins [13, 14]. Unlike ordered proteins, IDPs tend to have a higher
proportion of residues with charged and polar side chains which allow for the repulsion of
neighboring amino acids [13, 14]. They also have a lower number of residues that contain
hydrophobic and bulky aromatic side chains [14]. All of these differences help prevent the
formation of a compact structure and aids in maintaining their flexibility [14]. IDPs also
tend to have lower sequence complexity than ordered proteins [15-18]. These different
characteristics allow for the identification of disordered regions through the use of
algorithms with 75-80% accuracy [15-18].
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IDPs are widespread throughout nature and regulate many biological processes
such as transcription, translation, cell signaling, and cell proliferation. A higher percentage
of IDPs can be found more in eukaryotes than in prokaryotes or archaea [19, 20]. The
enrichment of IDPs within eukaryotes has been predicted to be due to increased cellular
organization [10, 20, 21]. Over one-third of eukaryotic proteins have been predicted to
have disordered regions of 30 residues or longer [9, 19, 22].
Structure and function
Amino acid residue composition of IDPs varies greatly when compared to ordered
proteins [23]. IDPs contain a low level of sequence complexity which exhibits a high level
of polar-charged residues and a low level of hydrophobic residues [14, 24]. Intrinsically
disordered regions (IDR) contain numerous structure interrupting amino acid residues like
prolines and glycines [14]. These amino acids aid in extending IDRs which allow binding
partners access to numerous attachment points. IDRs contain less bulky aromatic amino
acids than ordered regions and longer insertion and deletion regions [25]. In aqueous
solutions, all proteins maintain some degree of flexibility [26]. The presence of a high level
of polar-charged residues in IDPs allows for the repulsion of neighboring amino acid
residues, which aid in the prevention and destabilization of the formation of a compact
structure, thus maintaining their flexibility [23]. The flexibility of IDRs allows binding to
multiple protein partners, which is a common feature of IDPs [26]. Due to the constant
variation of structure conformations within IDPs, they do not maintain an equilibrium state
of their atoms and bond angles, thus making the phi and psi dihedral angles flexible,
which suggests that IDPs exist in a random coil state [8, 27]. IDPs cover a range of
different states from fully folded to partially folded [11, 22, 28, 29]. In addition to a lack of
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hydrophobic residues, most IDPs contain a large number of charged residues than
ordered proteins [17, 29]. This prevents the collapse of the protein through the repulsion
of like charged residues. There are some IDPs that possess a neutral net charge in
addition to few hydrophilic amino acid residues and these IDPs exist in collapsed forms
[29, 30]. They form random structures but contain no defined secondary structures and
are grouped in the pre-molten globule class of IDPs [22, 29, 30]. A special of class of
IDPs, termed molten globules, contain a high fraction of hydrophobic residues, but a low
level of folding. Within these IDPs energy exists in collapsed forms. They, unlike the premolten globule proteins, form stable secondary structures but unstable or no tertiary
interactions [29, 31].
Several attempts have been made to organize IDPs into various classes based on
varying degrees of dynamic behavior [19, 32]. Due to the different features of IDPs, i.e.
being completely unstructured, having some transient secondary structure, or being
configured in such a manner that ordered regions are joined together by flexible linkers,
it is difficult to group these proteins based on their structure, sequence, biophysical and
functional features [12]. Instead they are grouped into classes based on their evolution,
function, and protein interactions [12].
Even though IDPs do not form stable structures they make up a large class of
proteins that are functionally relevant. Many IDPs form numerous transient secondary
structures and are known to go through various amounts of PTMs [33-35]. Despite their
lack of structural stability, many IDPs undergo coupled folding and binding processes
when they are bound to their targets [10, 33, 34]. This coupled folding and binding is key
to the functional role IDPs play in cellular functions such as signaling and ligand
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recognition and binding, in addition to harboring PTMs and acting as protein network hubs
[33, 34].
Posttranslational modifications
Posttranslational modifications regulate the activity of IDPs [36, 37]. IDPs contain
an enormous amount of PTMs which suggests that IDPs play an important role in cell
signaling and regulation. Due to the increased flexibility of IDPs, as previously described,
protein modifiers like phosphatases, ubiquitinases, and kinases have easier access to
recognition and binding sites [38]. This flexibility also allows IDPs to take on various
conformations which enables the binding of multiple partners over a short sequence, in
addition to allowing IDPs to overcome steric hindrances in large complexes due to the
IDP being able to wrap around its binding partner [8, 19]. These features of IDPs make
them ideal for cellular processes involving PTMs, which require the binding of a protein
to multiple macromolecules like protein modifiers [19]. PTMs of proteins can lead to
conformational changes in IDRs and disorder to ordered transitions, and vice versa. This
in turn can affect the binding and function of ordered and disordered proteins [39]. It is
common for disordered regions to contain numerous phosphorylation sites. During
phosphorylation, the phosphate group contains a double negative charge that affects
protein conformation mainly due to the electrostatic effects that occur between the
phosphate and surrounding charged atoms of the protein [35, 40]. These conformational
changes can be local and/or long-range, effect protein-protein interactions, and increase
or decrease levels of disorder [35].

4

Coupled folding and binding
Many IDPs undergo coupled folding and binding when they are bound to their targets
[10]. This process involves the binding and folding of IDPs when they encounter their binding
partner. The coupled folding and binding process is best explained through two models,
conformational selection and induced fit [26, 41]. The conformational selection model is
based on the hypothesis that an IDP will fluctuate between different conformational states
that resemble the bound state leading to the binding of its protein partner [41]. In this model,
the conformation of the IDP is selected by the binding partner in which the IDP will fold and
then bind [41]. The induced fit model proposes an opposite type of interaction where the IDP
first binds to the protein partner making multiple weak interaction conformations, then
proceeds to fold into a tighter final bound state, in which it uses the binding partner as a
template [41].
Evolution of intrinsically disordered proteins
As compared to ordered proteins, IDPs tend to evolve faster due to the numerous
amino acid substitutions, insertions and deletions, and repeat expansions they encounter
[42-44]. Even with the many amino acid substitutions, IDPs remain unaffected due to
having fewer long-range intramolecular interactions and the lack of a hydrophobic core
unlike that of ordered proteins [45]. In spite of the high mutation rates of IDPs, certain
hydrophobic residues that they do contain like proline, leucine, phenylalanine, and
tryptophan are highly preserved suggesting their importance in IDP binding and function
[13, 19]. The evolutionary characteristics of IDPs may affect the evolution of PTMs that
are found within IDPs compared to those found within ordered proteins [42]. As more
information regarding the comparisons between homologous IDP families is discovered,
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more insight into their flexibility, coupled folding and binding, and overall function can be
provided.
Role in diseases
There are many diseases that are associated with IDPs and proteins containing
IDRs. Aggregates of α-synuclein protein are accumulated in Parkinson's disease,
Alzheimer's disease, and Down's syndrome [46-48]. Other IDPs associated with
neurodegenerative diseases include amyloid-β and tau proteins which are also involved
in Alzheimer's disease, prions which are associated with bovine spongiform
encephalopathy, and ataxin which plays a major role in spinocerebellar ataxia [49, 50].
Other pathogenic IDPs involved in human diseases are amylin (type II diabetes), HIV-1
Rev protein (AIDS) and CFTR (cystic fibrosis) [51-53]. A previous study found that within
an ordered/disordered protein, mutations within the IDRs can result in disease due to the
loss of PTM sites as well as the conversion from disorder to order [54]. This study showed
several mutations of IDPs that were associated with human diseases and are predicted
to cause disorder to order conversions such as tumor suppressor p53, Troponin I3, Breast
cancer type 1 susceptibility protein, and methyl CpG binding protein 2 [54].
p53 protein
p53 is an intrinsically disordered protein that acts as a tumor suppressor and cell
cycle regulator. p53 plays a vital role in protection from the development of cancer which
may arise from different types of cellular stress. The p53 pathway is frequently targeted
for genetic alterations in cancer. Approximately half of all human tumors express defective
p53 that have been mutated in its DNA-binding domain making it inactive as a
transcription factor [55]. Breast cancer, soft tissue, and bone sarcoma account for over
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50% of tumors in p53 mutation carriers, followed by adrenocortical carcinomas and brain
tumors [56]. This transcription factor is activated following stress in which it regulates
multiple downstream genes that are necessary for cell cycle control, antiangiogenesis,
senescence, and apoptosis.
Structure
Understanding the structure of p53 is imperative to understanding its function. p53
contains a natively disordered N-terminal transactivation domain (TAD), which can be
divided into two separate domains, TAD1 and TAD2. Following the TAD1 and TAD2
regions is a proline-rich region (PRR), which is connected to the structured DNA-binding
domain (DBD) and the tetramerization domains (TD), which are connected to one another
by a flexible linker region. The final domain of p53 is the regulatory carboxyl terminus
(REG), which is similar to the TAD region in that it is also intrinsically disordered (see
Figure 1). The TAD regions are essential for p53 transcriptional activity. They link gene
recognition with expression by binding directly to the transcriptional coactivators
p300/CREB-binding protein (CBP) as well as to other components of the basal
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Figure 1 – Human p53 domain structure. IUPred disorder prediction plot (top).
Domain structure of p53 corresponding to the residue positon of the overlaid
plot (bottom). Values above 0.5 are predicted to be disordered.
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transcription machinery [57, 58]. The TAD1 region becomes helical upon Taz2, Mdm2
and MdmX binding while the TAD2 region forms a helical structure upon binding to the
replication protein A and transcription factor II H protein [59-63].
Regulation
In normal cells, p53 is present at low concentrations whereas, under the condition
of cellular stress, such as DNA damage, p53 accumulates in the nucleus, where it is
active [64]. The activation of p53 can lead to different responses depending on the type
of cellular stress. DNA damage results in growth arrest in order for DNA to be repaired or
apoptosis [65]. Cells that lack functional p53 are unable to respond to stress appropriately
and this leads to the mutations and the development of cancer [66]. Under normal cellular
conditions, mouse double minute 2 homolog (Mdm2) is continuously degrading p53, thus
keeping p53 at low levels. p53 can transcriptionally activate Mdm2 resulting in the
inhibition of p53 activity by Mdm2. In turn Mdm2 functions as an E3 ubiquitin ligase that
recognizes the N-terminal TAD of p53 in which it is able to target p53 for degradation [67,
68]. Expression of Mdm2 initiates a negative feedback loop that regulates p53 and thus
controls the fate of the cell [69-71]. Mdm2 also acts as an inhibitor of p53 transcriptional
activation by binding to the p53TAD and inhibiting p53 mediated transactivation [72].
Mdm2 is also able to inhibit p53 transcriptional activity through its ability to transport p53
out of the nucleus to the cytoplasm due to its nuclear export signal [73, 74]. Mouse double
minute 2 homolog, Mdm4, also known as MdmX is an additional Mdm2 family member
that was also discovered to be an important negative regulator of p53. MdmX lacks the
ubiquitin E3 ligase activity and is unable to target p53 for ubiquitin-proteasome-dependent
proteolysis. However, MdmX is able to directly bind to p53 and inhibit its transcriptional
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activity which is a function that has been found to be independent of Mdm2 [75-77]. MdmX
can also stabilize Mdm2 by inhibiting the auto-degradation of Mdm2, which will increase
Mdm2 accumulation and lead to increased degradation of p53 [78, 79].
Function
The model of p53 activation (see Figure 2) shows that cellular stress like DNA
damage, activates signaling pathways that lead to the phosphorylation of the TAD regions
which inhibit Mdm2 and MdmX binding. Some cellular stressors that can lead to p53
activation are X-ray and UV radiation, low pH, chemotherapeutic DNA damaging drugs,
nitrous oxide, microtubule disruption, and prevention of RNA or DNA synthesis [1]. Since
different cellular stresses elicit different kinases, p53 is able to produce a specific
response based on which residues are modified and how they are modified [78-80]. Some
of the heavily studied PTMs within p53 are within the Mdm2/MdmX binding site (See
Figure 3). Numerous residues, serine and threonine, within the TAD are phosphorylated
in cells immediately following DNA damage [80-82]. Loss of S15 phosphorylation has
been shown to extend the half-life of p53 [83]. It is commonly known that the
phosphorylation of S15 and T18 play a critical role in preventing the interaction with Mdm2
[80, 84-87]. S33 is phosphorylated in response to UV and ionizing radiation [88]. There
has also been evidence that suggests p53 N-terminal phosphorylation can initiate Cterminal acetylation of the protein [88, 89]. The full schematic of p53 regulation is quite

9

complex and has yet to be completely understood, but the main mechanisms seem to
involve the interactions between p53, Mdm2, MdmX and the PTMs [74, 90].
A) Unstressed cell
Mdm2
Poly-U
TAD1

TAD2

PRR

DBD

TD

REG

TD

REG

Degradation
by
Proteasome

B) Cellular stress activates kinases

Kinases
PRR

DBD

Accumulation
and
Activation

P

TAD2

P

P

P

TAD1

Figure 2 – Model of p53 regulation. A. In normal cells, p53 is regulated and kept
at a low level by the E3 ubiquitin ligase MDM2, which marks it for ubiquitination
leading to p53 degradation. In turn, p53 activates the transcription of MDM2. In
stressful conditions, such as DNA damage, p53 level increase within the
nucleus, where it becomes active and induces cell growth arrest or apoptosis.
B. During cellular stress the activation of p53 occurs via several
posttranslational modifications including phosphorylation by kinases such as
ATM, ATR, Chk1 and MAPKs. This interrupts the Mdm2 binding leading to the
accumulation of p53 and its transactivation activity and possible cytoplasmic
roles. Figure adapted from Toledo et al. [3].
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Figure 3 – Well-known human p53 PTM sites and binding partners. The domains
of p53 are shown together with PTM sites and modifying kinases. Figure adapted
from Meek et al. [4].
Binding partners
As shown in Figure 3, p53 has many binding partners. Some of the most relevant
partners for this study, which are also some of the most studied partners are CREBbinding protein (CBP)/p300, Mdm2 and its homologue MdmX. As a dimer, Mdm2
functions as an E3 ubiquitin ligase. The p53 binding domain on Mdm2 is localized at the
N-terminus, from residues 1–118 or 19–102 [80, 81]. Mdm2 also contains an acidic
domain and a RING finger domain located at the C-terminal end of Mdm2 which houses
its ubiquitination function [80, 82, 83]. MdmX also functions as a dimer and has similar
11

domain structure to that of Mdm2, although it contains much less E3 ubiquitin ligase
function. As previously discussed, Mdm2 and MdmX play important roles in regulating
p53.
The phosphorylation of p53 at residue S15 increases interaction with CBP [84-86].
CBP is a transcriptional coactivator and histone acetyltransferase that facilitates
transcription initiation of p53 target genes and stabilizes p53 by acetylating its lysines that
would otherwise be ubiquitinated by Mdm2 [87, 88]. CBP contains four domains, KIX,
TAZ1, TAZ2, and IBiD, capable of binding to p53 within the TAD1 and TAD2 regions. It
has been proposed that all four domains may bind tetrameric p53 in the nucleus to
facilitate transcription initiation [89, 90]. Phosphorylation of the TAD1 region of p53
increases binding affinity with the KIX, TAZ1, and TAZ2 domains of CBP [85, 91]. Thus,
CBP competes with Mdm2 and MdmX for binding to p53 [90].
Thermodynamics of DNA binding specificity
The protein-DNA interaction is an intricate phenomenon that does not rely only on
structural analysis but involves thermodynamic factors to stabilize the bound complex
against the unbound complex. Protein–DNA interactions occur in one of two ways, either
through specific interaction, or non-specific interaction [92, 93]. In protein-DNA
interactions, the indirect and direct DNA specific base sequences are recognized through
hydrophobic interactions, the van der Waals attractions, and the non-specific electrostatic
interactions between the phosphate backbone of the DNA and the protein’s basic
residues [92]. The most intensively studied proteins that interact with DNA are
transcription factors. These proteins are able to make multiple contacts with the DNA
bases within the major groove of DNA where the bases are more accessible. This allows
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them to read the DNA sequence, which explains the binding specificity these transcription
factors have with DNA [93].
Full-length p53 contains two independently folding domains, the DBD and the TD
[94]. The high number of mutations within the sequence-specific DBD of p53 speaks to
the importance of DNA binding in the ability of p53 to transactivate genes [95, 96]. p53
polypeptides that contain both the DBD and the TD form stable p53-DNA complexes in
solution, having nanomolar affinity for sequence-specific DNA [97]. Inclusion of the Nterminal domain of p53 increases p53 DNA binding specificity, which is essential for p53’s
ability to differentiate the promoter sites of target genes [98].
Evolution of p53
p53 is well-conserved throughout evolution. The TAD region however is not as well
conserved as the ordered DBD region, which is common among IDRs. Compared to
IDPs, ordered proteins with just 30% sequence similarity usually have nearly identical
folds and functions [99, 100]. When looking at the p53 family, there are 3 members: p53,
p63, and p73 (Figure 4). Previous studies claim p63 to be the ancestral member while
p53 is the most recent member of the family [5, 101]. All 3 members contain an acidic Nterminal domain, DBD, TD, and REG. Unlike p53, the p63 and p73 genes contain a Cterminal sterile alpha motif (SAM) domain [101]. Figure 4 shows the structural alignment
for the domains and the approximate sequence similarity of the homologues. Such strong
similarities would suggest that the family would share functions. They all act as
transcription factors and have similar gene targets [101]. However, there are differences
between the genes. The TDs are similar between all three genes, however, p63 and p73
are not able to oligomerize with p53 even though they are able to form oligomers with
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each other [102]. p63 and p73 are both involved in the regulation of the cell cycle and the
induction of apoptosis, but unlike p53, p73 is rarely mutated in tumors and thus seems to
lack the effectiveness to induce apoptosis when compared to p53 [103].
p53

TAD

Identity
between
family
p63

PRR

~25%

TAD

Identity
between p63
and p73

~40%

p73

TAD

DBD

~65%

PRR

DBD

~85%

PRR

DBD

TD

REG

~35%

TD

REG

~50%

~60%

TD

SAM

REG

SAM

Figure 4 – p53 family domain structures. Comparison of the domain structures
within the p53 family. Figure adapted from Yang et al. [5].
Significance and IDP model protein
p53 can be a useful model for studying IDPs. In its monomeric state full-length p53
is predicted to have 50% disorder. The areas where most of this disorder is found is within
the TAD, TD and REG domains, while the DBD is considered to be ordered within the
monomeric state [95, 98, 104]. The TAD region contains transient helical structures and
numerous ligand binding sites [105-107]. The TAD domain of p53 contains many PTM
sites that regulate the binding events within the p53TAD [4, 90, 108, 109]. The Mdm2
binding site within p53 displays the strongest tendencies for secondary structure and
forms a stable alpha helix when bound by its Mdm2/MdmX protein partners [51, 89, 101].
Another major binding site is the DNA binding domain which participates in DNA binding
but also intramolecular binding to the N-terminal of p53 [102]. Long range interactions
that affect DNA binding have been observed between the disordered TAD and the
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ordered DBD regions of p53 [95, 98, 104]. The acidic domain of Mdm2 and MdmX inhibit
p53 DNA binding by interacting with the p53 DNA binding domain [104, 105].
Studying the TAD domain of p53 will help to improve our understanding of the
structure and function of not just p53 but other IDPs. Studying p53TAD allows us to further
understand a family of disordered regions that should have conserved function based on
the p53 sequence similarities which would allow for the observation across a large range
of sequence conservation. In addition to this, p53TAD serves as a great model for
understanding coupled folding and binding due to two binding sites that show coupled
folding and binding but differ in sequence identity, dynamic behavior, and structure.
Understanding the behavior of p53 and the secondary intramolecular and intermolecular
interactions that p53 is involved with will aid in understanding the regulation of p53 along
with similar phenomena in complexes containing multidomain IDRs.
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Chapter Two: Effects of phosphorylation on the structure of p53 transactivation
domain (p53TAD) and binding partners
Note to the readers: This chapter is comprised of prior published data, used with the
permission of the publishers [110].
Rationale
The disordered p53 transactivation domain (p53TAD) contains specific levels of
transient helical secondary structure that are necessary for its binding to its negative
regulators, Mdm2 and MdmX. The interactions of p53 with Mdm2 and MdmX are also
modulated

by

posttranslational

modifications

(PTMs)

of

p53TAD

including

phosphorylation at S15, T18 and S20 that inhibits p53-Mdm2 binding. It is unclear
whether the levels of transient secondary structure in p53TAD are changed by
phosphorylation or other PTMs. We used phosphomimetic mutants to determine if adding
a negative charge at positions 15 and 18 has any effect on the transient secondary
structure of p53TAD and protein-protein binding. The phosphomimetics reduced Mdm2
and MdmX binding affinity by 3-5-fold, but resulted in minimal changes in transient
secondary structure, suggesting that the destabilizing effect of phosphorylation on the
p53TAD-Mdm2 interaction is primarily electrostatic. Phosphomimetics had no effect on
the p53-KIX interaction, suggesting that increased binding of phosphorylated p53 to KIX
may be influenced by decreased competition with its negative regulators.
In this study, we used a combination of biophysical and structural methods to
obtain insights into the role of phosphorylation in modulating interactions of p53 with
Mdm2, MdmX, and CBP/KIX and the effect of phosphorylation on transient secondary
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structure. We assessed the effects of single- and double-site phosphomimetic mutations
of p53TAD upon binding to the N-terminal domain of Mdm2, MdmX, and the KIX domain
of CBP. Due to the location of S15 and T18 in a region of p53TAD containing transient
helical secondary structure and the importance of their phosphorylation for regulation, we
engineered p53TAD phosphomimetics, S15D and S15D/T18E, to determine if the
phosphomimicry of p53TAD at these sites affects protein-protein binding and changes
the levels of transient helical secondary structure. Our data shows that multisite
phosphomimicry reduces the binding affinity of p53TAD to Mdm2 and MdmX. In contrast
to earlier published results on p53 phosphorylation, single and multisite phosphomimetics
of p53TAD have equivalent, small effects on binding with KIX [85, 91, 111]. We observe
little, if any, change to the transient secondary structure of p53TAD.
Effects of PTMs on p53TAD and binding partners
Loss-of-function mutations in the p53 pathway frequently arise during cancer
development [55, 112, 113]. Approximately half of all human tumors express p53 mutants
with reduced DNA-binding affinity which reduces or eliminates transactivation [55, 114].
p53 is a well-known intrinsically disordered protein (IDP) whose disorder is a major
component of its functionality [8, 115]. An IDP is a protein that lacks a fixed or ordered
structure. IDPs are structurally very different from ordered proteins and tend to have
distinct properties in terms of function, sequence, interactions, evolution and regulation
[9, 11, 12]. Many IDPs like p53 form transient secondary structures and undergo coupled
folding and binding when they are bound to their targets [90, 116, 117]. IDPs cover a
range of different states from fully unstructured to partially structured [11, 28, 29].
Modulation of the degree of transient secondary structure affect p53’s interactions with
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its binding partners [118]. Studies showed that the levels of residual helicity in free p53
TAD are controlled by conserved prolines flanking the Mdm2/MdmX binding site [119].
The mutation of these prolines to alanine resulted in a higher p53TAD helicity and
increased Mdm2 binding [119]. Posttranslational modifications (PTMs) also regulate the
activity of IDPs [36, 37]. In normal cells, p53 is present at low concentrations due to its
interaction with the E3 ubiquitin ligase Mdm2; however, under stress conditions, p53
levels increase as it is phosphorylated, leading to its dissociation from Mdm2, migration
to the nucleus, and the transcriptional activation of its target genes [64]. Cells with mutant
or deleted p53 are unable to respond to stress appropriately, and this leads to mutations
and the development of cancer [66].
Mouse double minute 2 (Mdm2), also known as E3 ubiquitin-protein ligase Mdm2
proto-oncogene, and its homolog Mmd4, also known as MdmX, are negative regulators
of p53 [70, 120, 121]. Mdm2 is overexpressed in several human tumor types, such as soft
tissue sarcomas as well as breast tumors [122]. p53 levels are suppressed by the
Mdm2/MdmX heterodimer which promotes the polyubiquitination of p53 leading to its
degradation [75, 78]. Mdm2 and p53 are involved in an auto-regulatory feed-back loop
where p53 stimulates the expression of Mdm2; Mdm2, in turn, inhibits p53 activity
because it stimulates its degradation [67, 68]. MdmX lacks ubiquitin E3 ligase activity but
is able to directly bind to and inhibit p53 activity independently of Mdm2 [75-77]. DNA
damage activates kinases that phosphorylate p53 at residues S15, T18 and S20, which
stabilize and activate p53 by inhibiting Mdm2 binding [108, 123, 124]. In vitro, p53
phosphorylation affects its interaction with Mdm2, where phosphorylation of S15 and S20
residues individually result in a 2 and 1.5-fold reduction, respectively [91].
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Phosphorylation of T18 leads to a 19-22-fold reduction in binding affinity of p53TAD to
Mdm2, and one study has described an equivalent effect of phosphorylated T18 on Mdm2
binding to p53 [90, 91, 125]. Dually phosphorylated p53 at S15/T18 results in a binding
reduction equivalent to that of T18 alone, suggesting that T18 phosphorylation is the
driver of reduced binding affinity of p53 to Mdm2, though the T18 site of p53 cannot be
phosphorylated until the S15 site is phosphorylated first [91, 123, 126-129]. T18
phosphorylation creates additional charge-charge repulsion, creating an energetically
unfavorable environment for p53 and Mdm2 binding; however, the contribution of
phosphorylated p53’s structural changes to Mdm2 binding has not been assessed [123,
126-129].
Phosphorylation of p53TAD upon cellular stress leads to increased transcription of
its target genes and increased association with its coactivator, CREB binding protein
(CBP)/p300 [86]. CBP is a transcriptional coactivator and histone acetyltransferase that
facilitates transcription initiation of p53 target genes and stabilizes p53 by acetylating its
lysines that would otherwise be ubiquitinated by Mdm2 [87, 88]. CBP contains four
domains capable of binding p53TAD, and it has been proposed that all four domains may
bind tetrameric p53 in the nucleus to facilitate transcription initiation [89]. Whereas Mdm2
and MdmX interact with p53’s TAD1 region, which spans approximately residues 1-40,
the KIX, TAZ1, TAZ2, and IBiD domains of CBP interact with both TAD1 and TAD2 of
p53, approximately residues 41-60 [90]. Thus, CBP competes with Mdm2 and MdmX for
binding to p53, though it has also been shown that CBP and Mdm2 may form a ternary
complex with p53 in vitro [90]. Phosphorylation of the TAD1 region of p53 increases
binding affinity with the KIX, TAZ1, and TAZ2 domains of CBP, though possibly by
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different mechanisms [85, 91]. In this study we focus on KIX, for which the bound state of
p53 has not been determined. Phosphorylation of S15 or T18 is reported to result in a
1.7-4-fold increase in binding affinity with KIX, but an increase of 3-11-fold for the same
residues when binding to TAZ2. S15/T18 phosphorylation, however, has been reported
to result in 16 and 8-fold changes in binding affinity for KIX and TAZ2, respectively [85].
Likewise, where binding of p53 to the KIX domain is controlled by a combination of
conformational selection and electrostatic attraction, for example, TAZ2 interaction with
the phosphorylated T18 is likely driven by electrostatic attraction [61, 111, 130].
Dipole stabilization of the p53 N-terminal
During phosphorylation the phosphate group contains a double negative charge
that affects protein conformation mainly due to the electrostatic effects that occur between
the phosphate and surrounding charged atoms of the protein [35, 40]. These
conformational changes can be local and/or long-range, affect protein-protein
interactions, and increase or decrease levels of disorder [35]. As an extreme example of
the effect of phosphorylation of protein-protein interactions, PTM-mediated folding of the
IDP 4E-BP2 allows it to regulate translation initiation [37]. Multisite phosphorylation
stabilizes 4E-BP2 and decreases affinity to its binding partner elF4E by a factor of 4,000
compared to single-site phosphorylation which only decreased affinity by 100-fold [37].
Phosphorylation of T51 conforms PAGE4 into a more compact structure that still
maintains a flexible state for long range interactions. PAGE4 phosphorylation also
increases c-Jun transactivation but decreases the affinity of PAGE4 to c-Jun, which is
believed to occur due to the compact structure of PAGE4 [131]. This attenuation of
binding due to phosphorylation is common between many IDPs, which are known to form
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transient secondary structures and undergo coupled folding and binding when they are
bound to their targets [9-11]. p53TAD1 forms a short helix when bound to Mdm2 and
MdmX anchored via the hydrophobic residues F19, W23, L26, and TAD2 forms a short
helix when bound to the TAZ2 domain of CBP anchored around the hydrophobic residues
I50, W53 and F54 [62, 85]. Electrostatic interactions control the stability of the helix [132].
Such helices will have a macroscopic helical dipole with a partial positive charge at the
N-terminus and a partial negative charge at the C-terminus, which could stabilize the helix
dipole [133, 134].
Phosphomimetic mutations of p53
To study the effects of phosphorylation on protein structure and function
phosphomimetic mutations have been used extensively. Phosphomimetic mutations are
amino acid substitutions (Ser/Thr to Asp or Glu and Tyr to Glu) that mimic the effect of a
phosphorylated residue [135-137]. There are no natural amino acid side chains that
provide the combination of negative charge with a tetrahedral center. However, there are
numerous studies showing partial phenotypes when aspartic acid is substituted for
phospho-serine or glutamic acid is substituted for phospho-threonine [86, 138]. In our
phosphomimic mutants, the TAD1 helix, which corresponds to residues 19-25, has one
or two additional negative charges added towards the N-terminus. The addition of
negative charge might be thought to stabilize the helix as seen between antiparallel alpha
helices where the close proximity of opposing charges stabilizes each [134]. However,
computational studies have predicted that p53 T18 phosphorylation would destabilize the
helix by causing a long-range interaction with the K24 residue of p53, interfering with the
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D21 interaction with K24 [62]. Relatedly, phosphorylation of S20 is predicted to increase
helical propensity by stabilizing the D21-K24 interaction [132].
Transient secondary structure of p53TAD phosphomimetic mutants
We attempted in vitro phosphorylation experiments with NMR labeled p53TAD
using DNA-PK and CK1γ2 kinases to determine changes to transient secondary structure
but were unable to get 100% phosphorylation at either S15 or T18 compared to that of
previous studies (Figure S1) [139]. Therefore, we chose to use phosphomimetic
mutations. The phosphorylation of p53 makes it more negatively charged. In studying
protein phosphoregulation, it has become common to mutate phosphorylation sites to
phosphomimetic residues to attempt to study the constitutively phosphorylated state of
the protein [91, 136, 137, 140-144]. We designed p53TAD phosphomimetics (residues 173) by mutating S15 to Asp and S15/T18 to Asp/Glu, which will be referred to as S15D
and S15D/T18E, respectively. We used NMR spectroscopy to measure any changes in
the transient secondary structure of p53TAD wild type (p53TAD) and mutants. An overlay
of the 1H-15N heteronuclear single quantum coherence (HSQC) spectra of p53TAD and
the phosphomimetics is shown in Figure 5. The labeled peaks show the resonance
assignments of p53TAD residues (black peaks). There is hardly any shift in the majority
of the residues for the S15D (red peaks) and S15D/T18E (blue peaks) mutants compared
to p53TAD. We do see a significant shift at residues that are close to the mutated sites of
S15 and T18 suggesting that any structural effects from the mutation(s) will be local.
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Secondary chemical shift values were calculated using the prediction of
temperature, neighbor and pH-corrected chemical shifts for intrinsically disordered
proteins (POTENCI) software (Figure 2). This software calculates residue-specific
random coil chemical shifts from an amino acid sequence and these values are
subtracted from the NMR-measured chemical shift values to give the corrected secondary
chemical shift values [145]. Positive alpha carbon secondary chemical shifts are indicative
of alpha helix formation [146, 147]. All of the measured chemical shifts (NH, N, CA, CB,
and CO) were used to calculate the distribution of transient secondary structure using the

Figure 5 – p53TAD and phosphomimetics. 1H-15N HSQC spectra overlay
of 15N-labeled p53TAD (black), 15N-labeled S15D mutant (red), 15N-labeled
S15D/T18E mutant (blue).
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Figure 6 – Residue-specific secondary structure of p53TAD and
phosphomimetics. Secondary chemical shift plots and δ2D plot for p53TAD and
phosphomimetics determined from NMR spectroscopy. (A) p53TAD (B) S15D (C)
S15D/T18E. α-carbon secondary chemical shift (ΔδCα, black bars) and helical
δ2D plots (red line) for the p53TAD and phosphomimetics as determined by NMR
spectroscopy. Colored bars indicate binding sites for respective protein
partners. The α-carbon chemical shifts for p53TAD were collected on a 600 MHz
NMR at a digital resolution of 0.31ppm. The alpha carbon chemical shifts for
S15D and S15D/T18E were collected on an 800 MHz NMR at a digital resolution
of 0.27ppm.
δ2D software [148]. The negative charge produced during phosphorylation affects protein
conformation mainly due to the electrostatic effects and these changes can be local and
long-range [35, 40]. A short helix compromising residues 19-25 has one or two additional
negative charges added towards the N-terminus in our phosphomimetic mutants which
might stabilize the helix due to the close proximity of opposing charges. We observed
small differences in the transient helical secondary structure between p53TAD, S15D and
S15D/T18E (Figure 6). However, of the changes that were present most were within the
Mdm2/MdmX binding site. There was a slight increase in helicity for the mutants, with
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p53TAD having 36.4% helicity at its highest point and S15D and S15D/T18E having
39.8% and 39.9% helicity at their highest points, respectively, as indicated by the δ2d
plots (Figure 6 red line). The reported accuracy of δ2D is 2%. The changes in the
secondary chemical shifts, though minimal, were also observed within the Mdm2/MdmX
binding site (Figure 6 black bars).
Binding effects of phosphomimetic mutants
Next, we used isothermal titration calorimetry (ITC) to determine the effect of the
phosphomimetic mutations on p53TAD binding to Mdm2 (residues 17-125), MdmX
(residues 23-111), excluding the N-terminal “lid” and KIX (residues 586-672) (Figure 7)
[149-151]. Compared to qualitative methods of measuring protein-protein binding (e.g.
immunoprecipitation, western blot, GST pull-down) ITC is a widely used technique for
quantitative studies of an extensive variety of biomolecular interactions [119, 152-155]. It
is mostly used to observe the binding between molecules like protein and DNA by
measuring the binding affinity, enthalpy and stoichiometry of interacting molecules [152].
ITC measures the heat that is either expelled or consumed by the interaction of the
molecules present and modern ITC instruments make it possible to measure the
differences in heat as small as 0.1μcal (0.4 μJ) [156]. It can simultaneously determine
multiple binding parameters in a single experiment and does not require the modification
of binding partners with fluorescent tags or through immobilization; ITC measures the
affinity of binding partners in their native states. ITC experiments were performed by
titrating the p53TAD phosphomimetics into Mdm2, MdmX, and KIX. The ITC experiments
were performed in triplicate and the values averaged (Table 1). Data were analyzed with
the Origin70 ITC software from MicroCal and the integrated ITC data were fit with single-
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Figure 7 – Binding Isotherms of Mdm2, MdmX and KIX with p53TAD and mutants.
Isothermal calorimetry titrations of A. Mdm2 and p53TAD and mutants B. MdmX
and p53TAD and mutants and C. KIX and p53TAD and mutants.
site binding models. The stoichiometry ranged from 0.8 to 1.2. A standard deviation was
calculated for Kd using data from triplicate measurements. p53TAD and S15D bound
Mdm2/MdmX with similar affinities, whereas S15D/T18E

displayed a 2.5-4.5-fold

reduction with Mdm2 and a 5-fold reduction with MdmX (Figure 7A and 7B). Binding
affinity of p53 to KIX was similar between p53TAD and all the phosphomimetics. Binding
of p53TAD to KIX was endothermic with similar values for S15D (Figure 7C and Table 1).
S15D/T18E, however, was exothermic (Figure 7C and Table 1). Note that all variants of
p53 bind to KIX in a reaction that is endothermic at lower temperatures and transitions to
exothermic at higher temperatures (Data not shown). Interestingly, the phosphomimetics
had no effect on the transient helical secondary structure of p53TAD. Taken together, the
results argue that binding affinity between phosphorylated and unphosphorylated p53 to
Mdm2/MdmX is primarily controlled by electrostatics whereas the binding to KIX is not
improved by increased potential for electrostatic attraction.
Affinities of the p53TAD phosphomimetics for the KIX domain and the N-terminal
domains of Mdm2 and MdmX were determined by ITC (Figure 7). For both Mdm2 and
MdmX,
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Table 1 – ITC values for interactions between Mdm2, MdmX and KIX with p53TAD and mutants.
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S15D showed similar binding to p53TAD. S15D/T18E showed a decrease in binding to
Mdm2 and MdmX with binding being 4.5 times and 5 times weaker than p53TAD,
respectively (Table 1). Many studies have shown that phosphorylation of S15 and T18
play a critical role in preventing the interaction with Mdm2 [108, 126, 157]. There has
been some disagreement in regards to the impact of phosphorylation on binding; there is
a good consistency for unphosphorylated peptides (residues 10-57) binding to Mdm2 but
there is some variation in the phosphorylated peptides that does not appear to correlate
with different techniques or sizes of the peptides being used [85, 90, 158, 159]. Though
we do not see much structural change with the phosphomimetics, we do see binding
results consistent with other studies that phosphorylated p53 at the same residues.
Previous studies showed a 10-20-fold reduction in binding of p53 to Mdm2 due to p53
phosphorylation as compared to our results where we see a 3-5-fold reduction [85, 90,
158-160]. The results of our binding experiments with phosphomimetics are consistent
with previous findings suggesting that the phosphorylation of T18 is the driving force for
inhibiting Mdm2/MdmX binding [62, 123, 158-161]. Furthermore, there has not yet been
a quantitative study of the effect of p53 phosphorylation on MdmX binding. Our results
suggest that p53 phosphorylation may in some cases have an equivalent effect on MdmX
as on Mdm2.
Binding affinity of p53 to KIX was not significantly altered between p53TAD and
the phosphomimetics. We found p53TAD binds to KIX with a Kd of 11μM, similar to values
found in previous studies [90, 91, 111]. In contrast to previous studies on p53
phosphorylation, however, these phosphomimetic mutations increased binding affinity for
KIX by only 1.3-fold. Phosphorylation of p53 at S15 has been shown to result in a 1.7- 4-
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fold increase and S15/T18 phosphorylation results in a 16-fold increase in binding affinity
to KIX in vitro [85, 90, 91, 162]. The increase in binding affinity of phosphorylated p53 to
the domains of CBP has been attributed to an increase in electrostatic attraction
independent of site-specific affinity; however, it is unclear if this trend applies to KIX, which
has been suggested to have a relatively weak response to phosphorylation of p53
compared to other CBP/p300 domains [85]. Our results show that an increase in negative
charge of p53TAD alone is not sufficient to significantly increase binding affinity for KIX
[91]. Instead, it seems that the increase in binding affinity to KIX by p53 phosphorylation
may occur by way of a structural change that is not fully replicated in the phosphomimetics
produced here. We postulate that the phosphomimetics of p53 created here represent an
intermediate phenotype between that of phosphorylated and unphosphorylated p53 and
may be useful for future cell and molecular biology studies.
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Chapter Three: Intermolecular and intramolecular interactions between
phosphorylated p53, DNA and other binding partners
Rationale
There has been much controversy over whether the transactivation domain of p53
(p53TAD) has any effect on DNA binding. TAD1 and TAD2 interact with different
transcription factors such as TBP, TFIID, and coactivator p300/CBP. TAD2 contributes
significantly to p53 transcriptional activity and it is well known that W53 and F54 are key
residues for TAD2 function [89, 163]. Within the past decade studies have shown that the
transactivation domain of p53 (p53TAD) interacts with its DNA binding domain [104, 164,
165]. In vivo studies using proteolytic fragment release assays showed that p53TAD
bound to DBD at a higher concentration than DBD with C-terminal p53 [98]. This suggests
the TAD interacts with DBD more strongly than the C-terminus interacts with DBD [98].
Previous NMR binding experiments have shown that p53TAD interacts with the DBD and
binding experiments suggest that p53TAD is also involved in reducing sequence-specific
DNA binding by DBD [98, 104, 164]. Some studies suggest that it is not p53TAD that is
interacting with the DBD but instead the linker region between the PRR and the DBD
[164]. With the differences in results from current studies we decided to investigate the
TAD2 region of p53 and its interaction with the DBD.
PTMs of p53TAD are important not only for p53 binding to other partners but also
its function. Within p53 TAD1 the Mdm2/MdmX binding site contains some of the more
heavily studied PTMs. There has not been as much extensive work put into the
understandings of the PTMs within the p53 TAD2 region. We focused our study on the
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phosphorylation of p53 TAD2 in particular residue T55. During the recovery from the DNA
damage response TAF1 phosphorylation of T55 leads to the dissociation of p53 from
DNA [166]. T55 phosphorylation also leads to the dissociation of p53 from the p21
promoter [166]. Mdm2 binding has been shown to be increased in the presence of T55
phosphorylation [167]. The phosphorylation of S46 or T55 increases p53 binding to p62
and Tfb1 subunits of TFIIH [60]. The p53 transactivation domain (p53TAD) that contains
T55 interacts with several DNA-binding proteins such as replication protein A,
mitochondrial single-stranded DNA-binding protein, and the TfB1 subunit of transcription
factor II H [59, 168]. Although there is much evidence that p53 can be phosphorylated at
different sites, the results of these site-specific phosphorylation events are still poorly
understood. Due to studies like these, we propose that mutations within TAD2 combined
with site-specific phosphorylation can decrease p53 binding to DNA and promote binding
specificity.
In this study, we investigated the role of phosphorylation in modulating
interactions of p53 TAD2 with protein binding partners like Mdm2 and MdmX and the
effect of phosphorylation on p53-DNA binding. Due to the importance of T55, W53, and
F54 for transcriptional regulation, we engineered a p53TAD phosphomimetic mutant,
T55D, and to further determine the role of W53 and F54 in DNA binding we created a
NDQS construct where we mutated the tryptophan at residue 53 and the phenylalanine
at residue 54 to glutamine and serine respectively [89, 163]. We assessed the effects of
phosphomimetic mutations of p53TAD upon binding to the N-terminal domain of Mdm2
and MdmX. Using biophysical methods, we investigated the effects of point mutations
and phosphomimetic mutations on the interaction between p53 and DNA. Our binding
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data shows that phosphomimicry of the p53 transactivation domain decreases DNA
binding affinity, while substituting hydrophobic residues with polar residues within TAD2
of p53 increases DNA binding.
Model for the intramolecular interaction between p53 TAD2 and the DNA
binding domain of p53
There has been much controversy over whether the transactivation domain of p53
has any effect on DNA binding. The phosphorylation of T55 increases the negative
charges on p53 TAD2, which should increase its affinity for the DBD, thus increasing the
inhibitory effect on the DBD for DNA binding. With the inclusion of phosphorylation at T55

Figure 8 – A model for the interaction between DNA and the p53ND fragment and
the schematic of T55D-ND and NDQS mutations. A. The presence of DNA
displaces p53TAD from its interaction with DBD with the equilibrium favoring the
DNA-bound state. B. Phosphorylation of p53 at T55 or substitution of T55 with
the phosphomimetic mutant T55D inhibits binding of DNA to the DBD, where
equilibrium favors the intramolecular interaction. C. The schematic shows the
phosphorylation of TAD2 as indicated by the orange diamond. We created a
phosphomimetic mutation, T55D-ND, within TAD2 at residue 55 mutating it from
a threonine to an aspartic acid to mimic the phosphorylation of this site. The
green arrows indicate the mutations we made for our NDQS construct where we
mutated the tryptophan at residue 53 and the phenylalanine at residue 54 to
glutamine and serine respectively.
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we propose a model in Figure 8A and B for the interaction between DNA and p53 Nterminal domain (p53ND) and DNA and T55D-ND, respectively. Figure 8A suggests that
when residue T55 is not phosphorylated the DNA bound state is more favored, while in
Figure 8B we propose that the phosphorylation of T55 will cause a stronger intramolecular
interaction between the TAD2 region and the DBD of p53 than that of the p53-DNA bound
state, thus inhibiting the binding of DNA. These results are consistent with a model we
developed that describes how a direct intramolecular interaction between TAD2 and the
DNA binding domain influences DNA binding specificity. As performed in our previous
experiments we designed a phosphomimetic mutant to study the phosphorylated state of
p53. We created this p53 mutant (residues 1-312) by mutating T55 to Asp, which will be
referred to as T55D-ND (Figure 8C). In addition to studying phosphoregulation we also
wanted to understand the role that two consecutive hydrophobic residues within TAD2
(W53, F54), played in DNA binding. These residues are surrounded by acidic amino acids
and are essential for the activity of the transactivation domain [89, 163]. The second p53
construct we created contained the mutated sites of W53 and F54 to Gln and Ser
respectively (Figure 8C). This mutant will be referred to as NDQS.
NMR measurements of structure and dynamics of T55D-ND
We used NMR spectroscopy to measure any changes in the transient secondary
structure of p53ND and T55D-ND. An overlay of the 1H-15N heteronuclear single quantum
coherence (HSQC) spectra of p53ND and T55D-ND is shown in Figure 9. The labeled
peaks show the resonance assignments of the p53ND residues (blue peaks). We used a
phosphomimetic mutation to mimic phosphorylated p53 T55 to determine the effects that
this site-specific phosphorylation has on the structure of p53 (Figure 9 red peaks).
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Secondary chemical shift values were calculated using the prediction of temperature,
neighbor and pH-corrected chemical shifts for intrinsically disordered proteins (POTENCI)
software (Figure 10A and B black bars). All of the measured chemical shifts (NH, N, CA,
CB, and CO) were used to calculate the distribution of transient secondary structure using
the δ2D software (Figure 10A and B red line). This data shows that the phosphorylation
of residue 55 has little to no effect on the structure of p53 except in the region near the
mutated site. Due to a disappearance of peaks occurring near the mutated site we
performed NMR titrations to identify the effect this mutant had on DNA binding (Figure

1

15

Figure 9 – HSQC spectra of p53ND and T55D-ND mutant. H- N HSQC
spectra overlay of ND (blue) and T55D-ND (red).
11).
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A.

B.

Figure 10 – Residue-specific secondary structure of p53ND and T55D-ND. A.
Secondary chemical shift plots and δ2D plot for p53ND. B. Secondary
chemical shift plots and δ2D plot for T55D-ND. α-carbon secondary chemical
shift (ΔδCα, black bars) and helical δ2D plots (red line) for p53ND and T55DND as determined by NMR spectroscopy. Colored bars indicate binding sites
for respective protein partners.
We used NMR to investigate the effects of DNA binding on the change in structure
of p53ND and T55D-ND (Figure 11). There was no structural change in TAD of T55DND; however, the intensity ratios graph, calculated from the values given in the HSQC
spectra, shows disappearing peaks for T55D-ND near the mutated site (Figure 11 and
13). As shown by the red numbered residues in Figure 11, the addition of DNA makes
this region reappear. A plot of the averaged amide 1H and

15N

chemical shift changes

between the apo and DNA-bound p53ND and apo and DNA-bound T55D-ND shows the
largest chemical shifts are localized in the TAD2 region with maximum shifts observed for
residues 52-56 for both p53ND and T55D-ND (Figure 12). There is also significant
chemical shift changes within the PRR upon DNA binding, which is consistent with
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previously published data that suggests the PRR affects DNA binding [169, 170]. In
Figure 13 for p53ND the decrease seen in the TAD2 region suggests an association with
the DBD resulting in the lower peak intensities, but the intensity is increased when the
TAD2 residues are released from the DBD in the presence of DNA.

Figure 11 – HSQC spectra of ND and T55D-ND with decreasing amounts of
1
15
15
DNA. H- N HSQC spectra overlay of N labeled ND with consensus DNA at
15
15
100μM (black), N labeled T55D-ND with consensus DNA at 150μM (blue), N
15
labeled T55D-ND with consensus DNA at 100μM (red), N labeled T55D-ND with
consensus DNA at 75μM (green). The red numbers represent the residues that
are not present for the T55D-ND unbound spectra.
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Figure 12 – Chemical shift plot for p53ND and T55D-ND. Plot of the average amide 1H and 15N chemical
shift changes for TAD and PRR for the apo vs. DNA bound for p53ND (black bars) and T55D-ND (red
bars).
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Secondary chemical shift values were calculated using the prediction of temperature,
neighbor and pH-corrected chemical shifts for intrinsically disordered proteins (POTENCI)
software (Figure 11) [145-147]. All of the measured chemical shifts (NH, N, CA, CB, and
CO) were used to calculate the distribution of transient secondary structure using the δ2D
software [156].
PTM and DNA Binding specificity of p53ND mutants

Figure 13 – Intensity ratio of ND and T55D-ND bound and unbound to DNA. The
intensity ratios for TAD residues (1-74) were calculated from the values given for
the HSQC spectra of ND (black bars) bound and unbound to DNA, T55D-ND (red
bars) bound and unbound to DNA, and unassigned peaks are represented by
asterisks. The graph for T55D-ND shows disappearing peaks (yellow stars) near
the mutated site.
Recent studies showed that the presence of the N-terminal of p53 decreases DNA binding
affinity but increases binding specificity [98]. ITC was used to determine the effect of
mutations within the p53 N-terminal domain on DNA binding by titrating samples of either
the DBD, p53ND, T55D-ND, or NDQS with a 20-bp DNA fragment containing the
consensus binding site or a scrambled binding site (Table 2). Figure 14 shows the heat
traces from the ITC experiments. The presence of the N-terminal of p53 decreases
binding affinity of the DBD for consensus DNA by 29-fold and 39-fold for scramble DNA.
The phosphorylation of residue T55 within p53 decreases binding affinity of ND and DBD
for consensus DNA by more than 2.5-fold and 82-fold, respectively. The NDQS construct
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decreases binding affinity of DBD for consensus DNA by 14-fold and 63-fold for scramble
DNA. NDQS is also increased in binding affinity for consensus DNA by 2-fold compared
to ND. These results suggest that phosphorylating p53 T55 decreases DNA binding and
that residues 53 and 54 aid in the inhibition of DNA binding. The T55D-ND mutant shows
a decrease in DNA binding specificity compared to the other constructs we used. This
can be estimated by taking the ratio of Kd values for scrambled and consensus DNA. For
the p53ND, this ratio is 6.94, for the DBD, it is 3.42, for NDQS the ratio is 15.1, and for
T55D-ND the ratio is 3.4. This is an important finding as a decrease in binding specificity
would hinder the ability of p53 to discriminate the promoter sites of target genes.
Controlling for DNA quality
In performing any experiments it is always important to make sure that results are
reproducible. In this study we performed numerous ITC binding experiments with multiple
molecules. After performing a few experiments months apart we noticed some
inconsistencies with the data. We performed ITC experiments with differing
concentrations of consensus and scramble DNA and a few of the p53 constructs we
created. When comparing to the ITC results to DNA:protein concentration ratios we found
that for the consensus DNA:p53ND results, there was an increase in the enthalpy (ΔH),
entropy (TΔS), ΔG, and Kd values that shared a trend of increasing to the concentration
ration of about 2.5-2.7 and then gradually decreasing even with the increasing
concentration ratios (Figure 15). For the consensus DNA:DBD results

there is an

immediate increase to about the 2.7 ratio and then a plateau that occurs for the ΔG and
Kd values and a slight increase that occurs for ΔH and TΔS as the concentration ratio
reaches 3.7 (Figure 16). When the ITC values for consensus DNA:T55D-ND were
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Table 2 – ITC results of DNA binding affinity to p53 constructs. DNA binding affinity of ND (1–312), DBD (94–
312), T55D-ND (1-312), and NDQS (1-312) to the consensus DNA binding site and control scrambled DNA as
determined by ITC.
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A.

E.

B.

C.

D.

F.

G.

H.

Figure 14 – Binding Isotherms of DNA and p53 constructs. Isothermal calorimetry titrations of A.
Consensus DNA into DBD. B. Consensus DNA into p53ND. C. Consensus DNA into T55D-ND. D.
Consensus DNA into NDQS. E. Scramble DNA into DBD. F. Scramble DNA into p53ND. G. Scramble
DNA into T55D-ND. H. Scramble DNA into NDQS.
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analyzed we noticed an increase in all of the values and then a decrease around the 2.5
ratio and then another increase at the end as the concentration ratio continued to increase
(Figure 17). In addition to these varying results we tried to repeat previously performed
experiments and received very different results especially when working with scrambled
DNA (Table 3 and 4). The scramble DNA sample that was currently being used was
desalted or salt free. For the consensus DNA we were using a High performance liquid
chromatography (HPLC) purified sample. Desalting, or a salt free purification is a very
basic process of purification. Excess salt is removed from the sample using normal phase
chromatography. This process yields a salt-free sample that is useful for robust
techniques, but is unable to remove failed sequences that can possibly form during oligo
synthesis. The HPLC method purifies large amounts of oligonucleotides at high purity and
even removes shortmers and failed sequences from the sample. Once we noticed the
difference in DNA purity we performed the p53ND experiments with HPLC scramble DNA
and received the values shown in Table 2.
Table 3 – Previously published ITC results of DNA binding affinity to p53
constructs. DNA binding affinity of ND (1–312), DBD (94–312) to the consensus
DNA binding site and control scrambled DNA as determined by ITC.
p53 ND with
Consensus

p53 ND with
Scramble

DBD with
Consensus

DBD with
Scramble

Kd (nM)

188 ± 44.6

1540 ± 392

7.27 ± 2.5

25.4 ± 1.1

Stoichiometry

0.24 ± 0.01

0.26 ± 0.01

0.24 ± 0.01

0.24 ± 0.01

ΔG kcal/mol

-9.18 ± 0.14

-7.94 ± 0.16

-11.1 ± 0.20

-10.4 ± 0.03

ΔH kcal/mol

-9.6 ± 0.28

-9.2 ± 0.35

-16 ± 0.81

-15.6 ± 0.40

TΔS kcal/mol

-0.42 ± 0.41

-1.26 ± 0.47

-4.9 ± 0.67

-5.2 ± 0.42
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Table 4 – ITC results of DNA binding affinity to p53 constructs. DNA binding
affinity of ND (1–312), DBD (94–312) to the consensus DNA binding site and
control scrambled DNA as determined by ITC using lower purity scramble DNA
samples.
ND with
Consensus

ND with
Scramble

DBD with
Consensus

DBD with
Scramble

Kd (nM)

252.94 ± 72.08

471.75 ± 91.44

6.5 ± 1.12

47.78 ± 3.86

Stoichiometry

0.19 ± 0.002

0.27 ± 0.007

0.24 ± 0.01

0.21 ± 0.01

ΔG kcal/mol

-9.02 ± 0.19

-8.64 ± 0.11

-11.1 ± 0.10

-9.98 ± 0.04

ΔH kcal/mol

-8.95 ± 0.30

-3.35 ± 0.16

-14.54 ± 0.56

-15.41 ± 0.54

TΔS kcal/mol

0.07 ± 0.50

5.29 ± 0.22

-3.38 ± 0.46

-5.43 ± 0.59

Effect of p53 binding partners on p53-DNA binding
We were interested in how posttranslational modifications affect p53 and its
interaction with DNA and other binding partners like Mdm2. We performed ITC to
determine the effects p53-DNA binding would have on Mdm2 binding. This experiment
was performed by first preforming the titration between p53ND, T55D-ND, and NDQS
with consensus DNA, and then titrating Mdm2 into the preformed p53-DNA complex.
Table 5 shows that the addition of Mdm2 does not seem to affect the binding of p53ND
and NDQS with DNA with the Kd values for the ternary complex being similar to the values
for Mdm2 binding to p53ND and NDQS. This suggests that Mdm2 binding is not being
inhibited. The phosphorylation of p53 T55 seems to reduce the binding of Mdm2 this could
possibly be due to the binding of p53 TAD2 to DBD. This intramolecular binding could be
limiting access to the p53 TAD1 domain where Mdm2 binding site is located.
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Figure 15 – ITC results compared to the concentration ratio of DNA:p53ND titrated. Titration results of
consensus and scramble DNA into p53ND. All circles with no border represent titrations performed with
consensus DNA and p53ND. Circles with a black border represent titrations performed with scramble
DNA and p53ND. Error bars were calculated from triplicate measurements.
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Figure 16 – ITC results compared to the concentration ratio of DNA:DBD titrated. Titration results of
consensus and scramble DNA into DBD. All circles with no border represent titrations performed
with consensus DNA and DBD. Circles with a black border represent titrations performed with
scramble DNA and DBD. Error bars were calculated from triplicate measurements.
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Figure 17 – ITC results compared to the concentration ratio of DNA:T55D-ND titrated. Titration results
of consensus and scramble DNA into DBD. All circles with no border represent titrations performed
with consensus DNA and DBD. Circles with a black border represent titrations performed with
scramble DNA and DBD. Error bars were calculated from triplicate measurements.
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Table 5 – ITC results of ND and mutants with consensus DNA and the ternary complex of p53-Mdm2consensus DNA. DNA binding affinity of ND (1–312), T55D-ND (1-312), and NDQS (1-312) to the consensus
DNA binding site and Mdm2 (17-125) as determined by ITC.
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Chapter Four – Concluding statements
Preservation of p53 transient secondary structure
Through the use of phosphomimetic mutations we investigated the role of
phosphorylation on the binding of p53 with Mdm2, MdmX, and CBP/KIX and the effect of
phosphorylation on the transient secondary structure of p53. By increasing negative
charge of neighboring residues at the positive end (N-terminus) of the helical dipole
formed by p53 in the bound state with Mdm2, we expected a stabilization of the dipole in
accordance with what is seen in antiparallel helix interactions [134]. This change should
also increase the levels of transient helical secondary structure in unbound p53, which
we did not observe. Conversely, simulations suggest that phosphorylation of T18 has a
destabilizing effect on the helix in the bound state [123]. Our results show that neither an
increase nor decrease in transient helicity occurs for S15D or S15D/T18E. Though the
phosphomimetics of p53TAD did not show any major changes in structure it is important
to note that there were some minor chemical shifts (Figure 5 and 6). The most noticeable
shifts were within the Mdm2/MdmX binding site (Figure 6). Small shifts that were seen
outside of the Mdm2/MdmX binding site were less than the combined digital resolution of
the HSQC experiments. This suggests that any effects were local with no long-range
changes in structure, which is an expected result for a disordered protein such as p53.
The binding affinity of p53 to Mdm2 and MdmX was decreased in the presence of
the double phosphomimetic mutant, S15D/T18E (Figure 18B). The change in binding
affinity for Mdm2 and MdmX is more dramatic than that seen for KIX both here and in
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previously published studies, suggesting that where Mdm2 and MdmX compete with CBP
for binding to p53, phosphorylation of p53 may encourage binding to CBP through a
decrease in Mdm2 and MdmX binding more so than through an increase in CBP binding
[85, 91]. Additionally, there could be other factors at play that facilitate binding in vivo.
DNA binding specificity of p53
The p53 N-terminal region performs several important functions. TAD1 and TAD2
interact with different transcription factors such as TBP, TFIID, and coactivator p300/CBP
[86]. TAD2 contributes significantly to p53 transcriptional activity and it is well known that
W53 and F54 are key residues for TAD2 function [89, 163]. There has been much
controversy over whether the transactivation domain of p53 has any effect on DNA
binding. Within the past decade studies have shown that the transactivation domain of
p53 interacts with the DNA binding domain. Recent studies suggest that p53TAD is also
involved in increasing DNA binding specificity [98, 104]. We investigated the effects of
point mutations and phosphomimetic mutations on the interaction between p53 and DNA.
Our NMR data showed a disappearance of peaks near the mutated site in the absences
of DNA but a reappearance of the peaks as we increased DNA concentration (Figure 11,
12 and 13). The disappearance of the peaks within the TAD2 region of T55D-ND indicates
that this region is involved in some sort of intramolecular interaction with the DBD and
that DNA expels the TAD2 region of T55D-ND from the DBD which causes the peaks to
reappear in the presence of DNA. This data indicates that a change in structural
confirmation is not the cause of the T55D-ND inhibition of DNA binding but instead that
this could possibly be due to electrostatic shielding. Our binding data suggests that the
intramolecular interaction between p53TAD and DBD inhibits DNA binding and increases
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sequence specificity (Table 2). The NDQS construct increased DNA binding which
suggests that residues 53 and 54 play a role in inhibiting DNA binding (Figure 18A). The
inhibition of DNA binding is more pronounced with the phosphorylation of residue T55
(Table 2). Furthermore, TAD2 may use multiple weak interactions with the DBD to cause
a large effect on DNA binding affinity, which has been suggested in polyvalency models
[171].
p53-DNA interaction effects on protein-protein binding affinity

Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein
ligase MDM2 is a protein that in humans is encoded by the MDM2 gene [120]. MDM2 is
an important negative regulator of the p53 tumor suppressor and they are both a part of
an auto-regulatory feedback loop [70]. The disordered p53 transactivation domain
(p53TAD) contains specific levels of transient helical secondary structure that are
necessary for its binding to Mmd2. The interactions of p53 with Mdm2 are also modulated
by posttranslational modifications of p53TAD. It is unclear whether phosphorylated p53
bound to DNA can effect Mdm2 binding. We used binding experiments to assess how
posttranslational modifications effect p53 and its interaction with DNA and Mdm2 binding.
Using our p53ND fragment, phosphomimetic mutant T55D-ND and our NDQS mutant we
found that there was very little effect on DNA binding when Mdm2 was added to a
preformed complex of p53ND with DNA and NDQS with DNA (Table 5 and Figure 18C).
The binding results for the ternary complex was similar to that of Mdm2 binding to p53ND
and NDQS alone without the presence of DNA. For the T55D-ND with DNA complex there
seemed to be a decrease in Mdm2 binding compared to the other p53 fragments (Figure
18D). This could be due to the intramolecular interaction between TAD2 to DBD when
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Figure 18 – Schematic of p53ND mutant effects on DNA and protein-protein
binding affinity. A. The NDQS mutant results in the equilibrium favoring the DNAbound state. The green arrows indicate the mutations we made for our NDQS
construct. B. The schematic shows that the S15D/T18E (residues 1-73)
phosphomimetic mutation of TAD1 inhibits Mdm2 binding. C. The p53ND
construct does not affect DNA and Mdm2 binding. D. The T55D-ND
phosphomimetic mutant inhibits DNA and Mdm2 binding. Phosphomimetic
mutations are indicated by the orange diamonds.
T55 is phosphorylated. These results suggests that the phosphorylation of p53 T55
inhibits Mdm2 binding by restricting access to the TAD1 region of p53.
Concluding statements and future directions
In this report we have shown that PTMs and changes in protein disorder have an
effect on binding affinity of protein-protein interactions and DNA binding specificity. We
mimicked a state of phosphorylation through the use of phosphomimetic mutants that we
created to test the effects of phosphorylation on protein-protein binding and DNA binding.
In creating these mutants we in turn increased the negative charge associated with
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specific domains of the mutant fragments. This allowed us to also look at the effect of
protein disorder on protein structure and protein-DNA interactions. Our structural data did
not show any significant changes in structure with these mutants but there were a few
notable changes that were localized to the Mdm2/MdmX binding site. We showed that
the multi-site phosphorylation of p53TAD decreased binding to Mdm2 and MdmX. In
contrast, binding to KIX was unaffected by the mutants which suggests that p53 may
utilize certain PTMs like phosphorylation to enforce competitive binding between protein
binding partners like Mdm2/MdmX and CBP/p300.
We generated an additional phosphomimetic mutant to investigate the effects of
phosphorylation on DNA binding and protein-protein interactions. In addition to that we
also wanted to determine the effects on phosphorylation on the intramolecular binding
between the transactivation domain and the DNA binding domain of p53 that appears to
regulate the DNA binding specificity of p53. Our NMR data showed that the mutation we
created for our phosphomimetic mutant had no effect on the structure of our p53
construct, T55D-ND. We did however notice that residues near the mutated site were not
visible. With the addition of DNA the missing peaks on the NMR spectra reappeared. This
suggested that the T55D-ND mutant was engaging in some type of interaction at the
mutated site and in the presence of DNA this interaction is inhibited freeing the mutated
site from its previous interaction. Binding data showed that the phosphomimetic mutation
of p53 T55 had little effect on Mdm2 and MmdX binding. This was expected as this
mutation was not within the Mdm2/MdmX binding site and was thus not expected to
interrupt this binding. Our structural data in combination with our binding data suggest

52

that the intramolecular interaction between phosphorylated p53 TAD2 and DBD inhibits
DNA binding and the presence of the p53TAD increases DNA binding specificity.
In performing the DNA binding experiments we came across some inconsistencies
with our data which lead us to believe it had to do with the purity of our DNA samples.
Our numerous attempts to reproduce results was hindered by the purification technique
of our DNA samples. We found that even though we were using a non-consensus DNA
sample, the desalting/salt free purification was interfering with the binding of our protein
and actually increasing the binding affinity between our protein and the non-consensus
DNA which is the opposite reaction we expected. With a more purified sample of DNA we
were finally able to reproduce our results which are consistent with previously reported
studies.
In the future we plan to work with the desalting/salt free DNA to further understand
why this particular purification method produced such inconsistent results. We also would
like to investigate the effect of changes in ionic strength and how salt dependence affects
p53-DNA binding. This could also give insight into the results received from the
desalting/salt free purification. We would like to continue our work with identifying effects
of p53-DNA binding on protein-protein interactions by testing other p53 binding partners
like MdmX, KIX, TAZ1, and TAZ2. In doing this we will also be utilizing other techniques
such as fluorescence anisotropy to study these molecular interactions.
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Chapter Five: Methods/Protocols
Site directed mutagenesis
You will need:
-Forward and Reverse primers incorporating mutation
-QuickChange II (Agilent Technologies) kit
-Unmutated plasmid
-NZY+ Broth
Preparation of PCR reactions
Thaw reagents on ice
Prepare control reaction in a sterile microcentrifuge tube by adding:


2.5μl of 10X reaction buffer



2μl of (10ng) of pWhitescript 4.5-kb control plasmid (5ng/μl)



0.625μl (125ng) of oligonucleotide control primer #1 [34-mer (100ng/μl)]



0.5μl of dNTP mix



18.75μl of double-distilled water (ddH2O) to a final volume of 25μl

Prepare the sample reaction(s) by setting up a range of sample reactions using
various concentrations of template plasmid (e.g., 2.5, 5, 10, 25) while keeping the primer
concentration constant.
To each microcentrifuge tube add:


2.5μl of 10X reaction buffer



X μl @ ____ng of respective plasmid to respective tube
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0.5μl (125ng) of Forward mutant primer



0.5μl (125ng) of Reverse mutant primer



0.5μl of dNTP mix



Bring to a final volume of 25μl with ddH2O
Then add



0.5μl of PfuTurbo DNA polymerase (2.5U/μl) to each sample reaction and control
tube
Thermal cycling
Set up thermal cycler program using the following table:
Table 6 – Thermocycler program for site directed mutagenesis
Segment



Cycles

Temperature(°C)

Time (Seconds)

1

1

95

30

2

30

95

30

55

60

68

60/kb of plasmid

Types of mutation desired

Number of cycles

Point mutations

12

Single amino acid changes

16

Multiple amino acid deletions or insertions

18

Store on ice or in fridge until DpnI digestion
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DpnI digestion
The DpnI enzyme recognizes the methylated DNA of the template plasmids and
cleaves it in many places thus leaving only the mutated products of the PCR reaction
intact.


Add 0.5μl of DpnI enzyme (10U/μl) to each sample reaction and control tube



Spin down the reaction mixtures in each tube



Incubate each tube at 37°C for 1 hour with agitation
Transformation
The plasmids are transformed into XL-1 Blue supercompetent cells. These cells

were chosen for increased competency and their lack of certain recombinase enzymes
preventing the accumulation of mutations within plasmids. This allows for the long term
storage of stocks of transformed cells in frozen glycerol.


Add 25μl of XL-1 Blue supercompetent cells to a sterile microcentrifuge tube



Add 0.5μl of the DpnI digested sample to respective tubes and gently
tap/flick to mix
o 0.5μl of pUC18 control plasmid can also be added to 25 μl of XL-1
Blue supercompetent cells to verify the transformation efficiency



Incubate on ice for 30 minutes



Heat shock at 42°C for 30 seconds



Incubate on ice for 2 minutes



Add 125μl of NXY+ Broth preheated to 42°C to each tube



Incubate for 1 hour at 37°C while shaking at 225-250rpm
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For the mutagenesis and transformation controls, plate the entire volume of
cells on LB–ampicillin agar plates containing 80μg/ml X-gal and 20mM
IPTG



For the pUC18 control transformation, plate 5μl of cells on LB–ampicillin
agar plates containing 80μg/ml X-gal and 20mM IPTG (to help spread the
sample place a 200μl pool of NZY+ broth on the agar plate, pipet the 5 μl of
the transformation reaction into the pool, then spread the mixture)



For the sample reactions, plate the entire volume of each transformation
reaction on agar plates containing the appropriate antibiotic for the plasmid
vector



Incubate agar plates overnight (>16hours) at 37°C

For the mutagenesis and transformation controls, there should be 50-800 colonies
with 80% that are blue. For the pUC18 control transformation, there should be >250
colonies with >98% that are blue. For the sample reactions, there should be 10-1000
colonies present.
Minipreps
You will need:
-Fresh transformants (no older than 1 week)
-Enough buffer and columns in the Thermo Scientific GeneJET Plasmid Miniprep
kit for the number of reactions
-Sterile microcentrifuge tubes for plasmid product
-Overnight cultures
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Add 5ml of LB Broth + appropriate antibiotic for the plasmid vector to the respective
number of sterile labeled 15ml Falcon tubes for the respective number of reactions



Pick selected colonies from transformed plates and inoculate the respective
labeled tube



Incubate tubes overnight at 37°C while shaking at 150-170rp
For pelleting and lysis:


Centrifuge the 15ml Falcon tubes containing the 5ml overnight cultures for
5 minutes at 5,000rpm and discard the supernatant



For each tube resuspend the pelleted cells in 250μl of the Resuspension
Solution (Buffer P1) which should be stored in the fridge



Transfer each cell suspension to a sterile microcentrifuge tube



Add 250μl of the Lysis Solution (Buffer p2) and mix thoroughly by inverting
the tube 4-6 times until the solution becomes slightly clear and viscous



Add 350μl of the Neutralization Solution (Buffer N3) and mix thoroughly by
inverting the tube 4-6 times gently to avoid localized precipitation
DNA purification by spin column



Centrifuge each tube for 5 minutes at 13,000rpm and transfer the
supernatant (Avoid the white precipitate) to the supplied GeneJET spin
column



Centrifuge each tube for 1 minute and 13,000rpm and discard the flowthrough and reconnect the column



Add 500μl of the Wash Solution (Buffer PB) to each column
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Centrifuge each tube for 1 minute at 13,000rpm and discard the flowthrough and reconnect the column



Wash samples a second time by adding 500μl of the Wash Solution (Buffer
PB) to each column



Centrifuge each tube for 1 minute at 13,000rpm and discard the flowthrough and reconnect the column



Repeat the previous step to make sure all of the Wash Solution is removed



Transfer each column to a sterile microcentrifuge tube



Add 50μl of Elution Buffer (Buffer EB) to the center of the column (make
sure not to touch the membrane)



Incubate at room temperature for 2 minutes



Centrifuge each column for 2 minutes at 13,000rpm
DNA purity and sequencing

A nanodrop should be used to measure the concentration and purity of the plasmid
DNA. The purity is determined by the ratios of the absorbance at various wavelengths.
The ratio of 260nm/230nm estimates the organic solvent contamination and a ratio of
greater than 2.0 is desired. The ratio of 260nm/280nm estimates the protein
contamination and a ratio of greater than 1.8 is desired. Plasmids should be stored in the
fridge (-20°C) until later use. To verify plasmid integrity the plasmid samples should be
run on a 1% agarose gel in Tris Boric EDTA (TBE) at 100 Volts for 2 hours.
Plasmid samples that have adequate purity and integrity are shipped to
Eurofins MWG Operon for sequencing to confirm that the plasmid has the correct
sequence.
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Protein purification and Sample preparation
All orthologues that contained a His-tag were expressed using Novagen’s pET
Vector System, specifically pET-28A plasmid seen in Figure 19. The vector contains a
Kanamycin resistance selection site and a T7 promoter followed by a six-histidine tag,

Figure 19 – pET-28A vector [2]. All sequences containing a His-tag were inserted
between the Nde l and Xho l restriction sites of this vector.
thrombin cleavage site, and multiple cloning site for expression, purification, and cloning
purposes. All orthologues that contained a GST-tag were expressed using SigmaAldrich’s
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Figure 20 – pGEX vector [1]. All sequences containing a GST-tag were inserted
between the BamH I and Xho l restriction sites of this vector
pGEX Vector System, specifically pGEX-6p-2 plasmid seen in Figure 20. The vector
contains a Ampicillin resistance selection site and a tac promoter, that is induced by the
lactose analog isopropyl β-D-thiogalactoside (IPTG). This vector also contains an internal
lacIq gene. The lacIq gene product is a repressor protein that binds to the operator region
of the tac promoter, which prevents expression until it is induced by IPTG. This maintains
control over the expression of the insert. The plasmids are transformed into BL21 (DE3)
chemically competent E. coli cells using standard heat shock and SOC recovery
protocols. These cells contain the T7 polymerase gene which is regulated by the lacUV5
promotor which allows lactose or IPTG to induce the expression of the T7 polymerase.
All of our sequences have been codon optimized.
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Transformation


Add 20μl of BL21 (DE3) cells from New England Biolabs to 2μl of 1ng/μl of
desired plasmid in a sterile microcentrifuge tube
o For the control, only add the cells not plasmid



Incubate on ice for 15 minutes



Heat shock at 42°C for 30 seconds



Incubate on ice for 2 minutes



Add 100μl of SOC media (or NXY+ Broth) preheated to 37°C to each tube



Incubate tubes for 1 hour at 37°C while shaking at 200-220rpm



Plate the entire volume of each transformation reaction on agar plates
containing the appropriate antibiotic for the plasmid vector



Incubate agar plates overnight (>16hours) at 37°C

Expression and Lysis
All cell growth experiments were performed in M9 media. In order to make
15N-

labeled or
0.2% (w/v)

and

13C-labeled

13C-labeled

samples 1g/L of

15N-labeled

15N-

ammonium chloride and/or

glucose were added in the place of nitrogen and carbon sources

(Cambridge Isotopes). Preparing Stock Salt Solutions for pET-28A vector samples:
To make 2L of 10X M9 Salts:


120g – Na2HPO4



60g – KH2PO4



10g – NaCl



bring to 2L with ddH2O



pH to 7.1 with HCl and filter sterilize
62

Make and filter sterilize the following solutions separately with ddH2O:


1M MgSO4



20% Destrose- Glucose



50mM CaCl2



289.5M FeCl3 (in 0.1M HCl to prevent precipitation)



5mg/ml Vitamin B (protect from light and store at 4°C)

Preparing 2L of M9 Media for pET-28A vector samples:


To 1.7L ddH2O add 200ml of 10X M9 salts



4ml 1M MgSO4



4ml 50mM CaCl2



2ml 0.01M FeCl3



400μl Vitamin B (5mg/ml stock)



If working with a double labeled sample take a 2ml sample of contents
already mixed before adding the labeled glucose. If the sample is not
labeled continue adding contents below.





Add 4g of dry Dextrose-Glucose (20ml of 20% stock)



pH between 7.3-7.5 (7.35 is the optimal pH that reduces salt precipitation)

Add 2ml of M9 media to sterile 15ml Falcon tube and label this control “Glucose
only”


Add 2g Ammonium Chloride (NH4Cl)



pH between 7.3-7.5 (7.35 is the optimal pH that reduces salt precipitation)



Add 2ml of M9 media to sterile 15ml Falcon tube and label this control
“Glucose + Nitrogen”
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Add 1mL of antibiotic of choice (pET-28A vector is Kanamycin resistant)



Add 2ml of M9 media to sterile 15ml Falcon tube and label this control
‘”Antibiotic added”



Bring to 2L with ddH2O and filter sterilize into 2 1L bottles



Inoculate the controls labeled “Glucose only” and “Glucose + Nitrogen” with
freshly transformed colonies (no older than 1 week)



Incubate all controls overnight at 37°C while shaking at 150-170rpm



Add 25ml of the M9 Media from each 1L bottle to a flask and inoculate the
flask with freshly transformed colonies (no older than 1 week)



Incubate the flask overnight at 37°C while shaking at 150-170rpm



Place the remaining amount of M9 Media in a 37°C incubator overnight
Expression of pET-28A vector samples



Check the controls to make sure there is minimal growth in the control labeled
“Glucose only”, growth in the control labeled “Glucose + Nitrogen”, and no growth
in the control labeled “Antibiotic added”



Measure the OD@600nm (flow path of 1cm) of the overnight cultures in the flasks
(should be over 1.00)



Place the remaining M9 Media that was stored in the incubator into 2 large flasks
that were placed in a 37°C incubator shaking at 150-170rpm



Inoculate the media to a starting point of 0.04 OD



Monitor the OD periodically (usually doubles every hour)



Once the OD of 600 is reached, place 300μl of the culture into a microcentrifuge
tube and centrifuge for 2 minutes at 12,000rpm and discard the supernatant. This
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pre-induction sample will be stored for SDS-PAGE analysis to compare to samples
taken during and post-induction to determine conditions necessary for maximum
protein expression.
o For KIX, once the OD of 600 is reached, place culture in a 15°C incubator
shaking at 150-170rpm. Place 300μl of the culture into a microcentrifuge
tube and centrifuge for 2 minutes at 12,000rpm and discard the supernatant.


Induce culture with 1mM IPTG final concentration



When working with a new mutant take 300μl samples of the culture each hour for
SDS-PAGE analysis. p53TAD constructs showed maximum expression at 6 hours.
KIX fully expresses after 22 hours.



Pellet cultures at 8,000rpm for 5 minutes each spin



Remove supernatant after each spin and when the entire culture has been
pelleted, freeze pellet at -80°C for no more than 1 month before purification
Preparing Stock Salt Solutions for pGEX vector samples:

To make 0.1L of Metal Stock Solution:


8ml – concentrated HCl



5g – FeCl2 • 2H2O



184mg – CaCl2 • 2H2O



4mg – H3 BO3



40mg – MnCl2 • 4H2O



18mg – CoCl2 • 6H2O



4mg – CuCl2 • 2H2O



340mg – ZnCl2
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605mg – Na2 MoO4 • 2H2O



Fill to 100ml with ddH2O
To make “O” solution:


10ml – Metal Stock Solution



26.8g – MgCl2 • 6H2O



Fill to 500ml with ddH2O

To make “S” solution:


4.8g – K2SO4



Fill to 100mL with ddH2O
To make “Salt” solution:



16.5g – KH2PO4 (MONOBASIC)



87.7g – K2HPO4 (DIBASIC)



18.25g – NaCl



Fill to 500mL with ddH2O



pH to 7.5

Preparing 2L of M9 Media for pGEX vector samples:


To 1880ml of ddH2O add 80ml of “Salt” solution



2ml “S” solution



4ml “O” solution



400μl Vitamin B (5mg/mL stock)



If working with a double labeled sample take a 2mL sample of contents
already mixed before adding the labeled glucose. If the sample is not
labeled continue adding contents below.
66



Add 4g of dry Dextrose-Glucose (20ml of 20% stock)



pH between 7.3-7.5 (7.35 is the optimal pH that reduces salt precipitation)



Add 2ml of M9 media to sterile 15ml Falcon tube and label this control
“Glucose only”



Add 2g Ammonium Chloride (NH4Cl)



pH between 7.3-7.5 (7.35 is the optimal pH that reduces salt precipitation)



Add 2ml of M9 media to sterile 15ml Falcon tube and label this control
“Glucose + Nitrogen”




Add 1mL of antibiotic of choice (pGEX vector is Ampicillin resistant)

Add 2ml of M9 media to sterile 15ml Falcon tube and label this control ‘”Antibiotic
added”


Bring to 2L with ddH2O and filter sterilize into 2 1L bottles



Inoculate the controls labeled “Glucose only” and “Glucose + Nitrogen” with
freshly transformed colonies (no older than 1 week)



Incubate all controls overnight at 37°C while shaking at 150-170rpm



Add 25ml of the M9 Media from each 1L bottle to a flask and inoculate the
flask with freshly transformed colonies (no older than 1 week)



Incubate the flask overnight at 37°C while shaking at 150-170rpm



Place the remaining amount of M9 Media in a 37°C incubator overnight
Expression of pGEX vector samples



Check the controls to make sure there is minimal growth in the control labeled
“Glucose only”, growth in the control labeled “Glucose + Nitrogen”, and no growth
in the control labeled “Antibiotic added”
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Measure the OD@600nm (flow path of 1cm) of the overnight cultures in the flasks
(should be over 1.00)



Place the remaining M9 Media that was stored in the incubator into 2 large flasks
that were placed in a 37°C incubator shaking at 150-170rpm



Inoculate the media to a starting point of 0.04 OD



Monitor the OD periodically (usually doubles every hour)



For Mdm2/MdmX constructs, once the OD of 600 is reached, place flasks in a 15°C
incubator shaking at 150-170rpm. Place 300μl of the culture into a microcentrifuge
tube and centrifuge for 2 minutes at 12,000rpm and discard the supernatant. For
p53ND constructs, once the OD of 500 is reached add 200μl of 100mM ZnCl 2 per
liter of culture and transfer culture to cold incubator set to 15°C and continue
growing the culture until the OD of 600 is reached. Place 300μl of the culture into
a microcentrifuge tube and centrifuge for 2 minutes at 12,000rpm and discard the
supernatant. The pre-induction sample will be stored for SDS-PAGE analysis to
compare to samples taken during and post-induction to determine conditions
necessary for maximum protein expression.



For Mdm2/MdmX constructs, induce culture with 1mM IPTG final concentration.
For the p53ND constructs, wait 15-30 minutes then induce culture with 1mM IPTG
final concentration.



For the Mdm2/MdmX constructs, the culture will express for 18 hours. For the
p53ND constructs, the culture will express for 20 hours.



Pellet cultures at 8,000rpm for 5 minutes each spin
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Remove supernatant after each spin and when the entire culture has been
pelleted, freeze pellet at -80°C for no more than 1 month before purification
Nickel column and Thrombin cleavage
To prepare the Nickel column buffers for samples containing a His-tag:
To make 2L of Nickel Lysis buffer:


To 800ml of ddH2O add 50mM Sodium Phosphate Monobasic Monohydrate
(13.79g)



300mM NaCl (35.064g)



10mM Imidazole (1.36g)



0.02% Sodium Azide (2mL of 20% stock)



Bring to 2L with ddH2O



pH to 8 and filter sterilize into 2 1L bottles

To make 1L of Nickel Elution buffer:


To 800ml of ddH2O add 50mM Sodium Phosphate Monobasic Monohydrate
(6.895g)



300mM NaCl (17.532g)



250mM Imidazole (17.02g)



0.02% Sodium Azide (1mL of 20% stock)



Bring to 1L with ddH2O



pH to 8 and filter sterilize into a 1L bottle

To make 2L of Gel Filtration buffer:


To 800ml of ddH2O add 50mM Sodium Phosphate Monobasic Monohydrate
(13.79g)
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300mM NaCl (35.064g)



1mM EDTA (4mL of 500mM stock)



0.02% Sodium Azide (2mL of 20% stock)



Bring to 2L with ddH2O



pH to 7 and filter sterilize into 2 1L bottles

Lysis, Pre-Cleave Nickel column, Thrombin cleavage, Post-Cleave Nickel
column, and Size Exclusion column
 After expression, suspend pellets in 25mL of Nickel lysis buffer containing
1 protease inhibitor tablet (SigmaAldrich) per liter of culture
 Lyse with a French Press pressure cell using a minimum pressure of
20,000psi.
 Centrifuge the sample at 38,720g for 1hr to isolate the soluble fraction
 Filter the supernatant and add to a column containing 30ml of Ni-NTA
Superflow resin (Qiagen). All buffers used on the Ni-NTA column were run
at a flow rate of 3ml/min. Table 7 shows the program guidelines of the precleave Nickel column.
Table 7 – Nickel column (pre-cleave) program guidelines
Step
Equilibrate
Inject
Wash
Elute
Reequilibrate
Volume
1 CV*
1 CV* + 2 CV*
3 CV*
3CV*
Sample
Volume
Buffer
Lysis
Lysis
85% lysis and 15% Elution Lysis
elution mixed by the
FPLC system
*The column volume (CV) is 30ml of Ni-NTA Superflow resin (Qiagen) that is used.


Analyze fractions of peaks seen on the chromatogram using PAGE and
combine the fractions containing the protein
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Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a final volume of 8ml.



Dialyze sample overnight into gel filtration buffer using 3500Da MWCO
dialysis tubing (FisherBrand).



Remove

HIS-tag

from

protein

with

the

Sigma-Aldrich

Thrombin

CleanCleave Kit (RECOMT).
o Wash Thrombin beads with dialysate from dialyzed sample, and
place the mixture in a 15ml Falcon tube
o Centrifuge tube for 5 minutes at 1000rpm at 4°C
o Discard supernatant and wash beads again with fresh dialysate
o Centrifuge tube for 5 minutes at 1000rpm at 4°C
o Discard supernatant and wash beads again with fresh dialysate
o Centrifuge tube for 5 minutes at 1000rpm at 4°C
o Before adding the dialyzed sample to the thrombin bead remove 1530μl of the pre-cleaved sample for SDS-PAGE analysis and
comparison with the post-cleave sample.
o Discard supernatant and add dialyzed sample to Thrombin beads.
o Place the tube on platform rocker for 4 hours (p53TAD WT) or
overnight (other p53TAD mutants) and for 2 hours for KIX.
o Run the solution through the Thrombin column to retrieve the cleaved
sample in a fresh 15ml Falcon tube and rinse the tube with the
dialysate to collect residual protein in the tube to run through the
Thrombin column.
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o Place 2ml of the dialysate in the column to collect in a waste
collection tube.
o Add 2ml of the Thrombin Regeneration Buffer 1 to the column and
allow it to flow through to the waste collection tube.
o Add 2ml of the Thrombin Regeneration Buffer 2 to the column and
allow it to flow through to the waste collection tube.
o Add another 2ml of the Thrombin Regeneration Buffer 2 to the
column and allow it to flow through to the waste collection tube.
o Add 2ml of the Thrombin Storage Buffer to the column and allow it to
flow through to the waste collection tube.
o Cap the column and add 2ml of the Thrombin Storage Buffer to the
column and mix to loosen the beads then transfer them to the
provided Thrombin kit container and store in -20°C.


Verify the completion of the cleavage reaction by taking a 15-30μl sample
for SDS-PAGE analysis.



Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a final volume of ~4-6ml.



Load concentrated sample onto 120ml of GE HiLoad 16/60 Superdex 75
resin (size exclusion column). The 2ml injection volumes should be run at a
flow rate of 1ml/min. Table 8 shows the program guidelines of the column.

Table 8 – GE HiLoad 16/60 Superdex 75 column program guidelines
Step
Equilibrate Inject
Elute
Reequilibrate Inject
Elute
Volume
1.25 CV*
2ml
1.5 CV*
0.25 CV*
2ml
1.5CV
*The column volume (CV) is 120ml of GE HiLoad 16/60 Superdex 75 column that is used.
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Analyze fractions of peaks seen on the chromatogram using SDS-PAGE
and combine those fractions containing the protein.



Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a final volume of ~5ml.



Dialyze samples in NMR buffer or ITC buffer overnight using 3500Da
MWCO dialysis tubing (FisherBrand).

To prepare 1L of NMR buffer p53TAD constructs:


50mM Sodium Phosphate Monobasic Monohydrate (6.895g)



50mM NaCl (2.922g)



1mM EDTA (2mL of 500mM stock)



0.02% Sodium Azide (1mL of 20% stock)



Bring to 2L with ddH2O



pH to 8 and filter sterilize into 1L bottle

To prepare 2L of ITC buffer for p53TAD constructs:


50mM Sodium Phosphate Monobasic Monohydrate (13.79g)



150mM NaCl (17.532g)



1mM EDTA (4mL of 500mM stock)



0.02% Sodium Azide (2mL of 20% stock)



Bring to 2L with ddH2O



pH to 8 and filter sterilize into 2 1L bottles

Finally concentrate to desired NMR or ITC concentration or freeze with 50%
glycerol in -80°C.
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Glutathione S-transferase, Anion Exchange, and size exclusion columns
To prepare the GST column buffers for samples containing a GST-tag:
To make 2L of GST-A buffer for Mdm2/MdmX:


25mM Tris Base (6.057g)



25mM Tris Hydrochloride (7.88g)



300mM NaCl (35.064g)



1mM DTT (0.3085g)



0.02% Sodium Azide (2mL of 20% stock)



2.5mM EDTA (10mL of 500mM stock)



Bring to 2L with ddH2O



pH to 7.4 and filter sterilize into 2 1L bottles

To make 0.250L of GST-B buffer for Mdm2/MdmX:


25mM Tris Base (0.757g)



25mM Tris Hydrochloride (0.985g)



300mM NaCl (4.383g)



1mM DTT (0.0385g)



10mM Reduced Glutathione (0.768g)



0.02% Sodium Azide (250μL of 20% stock)



2.5mM EDTA (1.25mL of 500mM stock)



Bring to 0.250L with ddH2O



pH to 7.4 and filter sterilize into a 250ml bottle

To make 2L of Gel Filtration buffer for Mdm2/MdmX:


50mM Sodium Phosphate Monobasic Monohydrate (13.79g)
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300mM NaCl (35.064g)



1mM EDTA (4mL of 500mM stock)



0.02% Sodium Azide (2mL of 20% stock)



Bring to 2L with ddH2O



pH to 7 and filter sterilize into 2 1L bottles

To make 2L of GST-A buffer for p53ND constructs:


25mM Tris Base (6.057g)



25mM Tris Hydrochloride (7.88g)



300mM NaCl (58.44g)



1mM DTT (0.3085g)



0.02% Sodium Azide (2mL of 20% stock)



20μM ZnCl2 (400μl of 100mM stock)



Bring to 2L with ddH2O



pH to 7.4 and filter sterilize into 2 1L bottles

To make 0.250L of GST-B buffer for p53ND constructs:


25mM Tris Base (0.757g)



25mM Tris Hydrochloride (0.985g)



300mM NaCl (7.305g)



1mM DTT (0.0385g)



10mM Reduced Glutathione (0.768g)



0.02% Sodium Azide (250μL of 20% stock)



20μM ZnCl2 (50μl of 100mM stock)



Bring to 0.250L with ddH2O
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pH to 7.4 and filter sterilize into a 250ml bottle

To make 2L of Anion Exchange Load buffer for p53ND constructs:


20mM Tris Base (4.85g)



0.02% Sodium Azide (2mL of 20% stock)



20μM ZnCl2 (400μl of 100mM stock)



1mM DTT (0.3085g)



Bring to 2L with ddH2O



pH to 7 and filter sterilize into 2 1L bottles

To make 1L of Anion Exchange Elution buffer for p53ND constructs:


20mM Tris Base (2.425g)



1M NaCl (58.44g)



0.02% Sodium Azide (1mL of 20% stock)



1mM DTT (0.154g)



20μM ZnCl2 (200μl of 100mM stock)



Bring to 1L with ddH2O



pH to 7 and filter sterilize into a 1L bottle

To make 2L of Gel Filtration buffer for p53ND constructs:


50mM Sodium Phosphate Monobasic Monohydrate (13.79g)



300mM NaCl (35.064g)



0.02% Sodium Azide (2mL of 20% stock)



2mM DTT (0.617g)



Bring to 2L with ddH2O



pH to 7 and filter sterilize into 2 1L bottles
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Lysis, GST column, Anion Exchange column and Size Exclusion column


After expression, suspend pellets in 25mL of GST-A buffer containing 1
protease inhibitor tablet (SigmaAldrich) per liter of culture.



Lyse with a French Press pressure cell using a minimum pressure of
20,000psi.



Centrifuge the sample at 38,720g for 1hr to isolate the soluble fraction.



Filter the supernatant and apply to a column containing 10ml Glutathione
Sepharose 4 Fast Flow resin. The injection volumes should be run at a flow
rate of 2ml/min and the buffers are run at 4.5ml/min. Table 9 shows the
program guidelines of the column.

Table 9 – GST column (pre-cleave) program guidelines
Step
Equilibrate Inject/flowWash
Elute
Reequilibrate
through
Volume 2 CV*
25ml
2.5 CV*
3.5 CV*
1.25 CV*
Buffer
Lysis
Lysis
Lysis
Elution
Lysis
*The column volume (CV) is 25ml Glutathione Sepharose 4 Fast Flow resin that is used.


Analyze fractions of peaks seen on the chromatogram using PAGE and
combine the fractions containing the protein.



Dialyze the sample overnight into GST-A buffer using 3500Da MWCO
dialysis tubing (FisherBrand) and add a 1:100 ratio of HRV3C protease to
cleave the GST tag.



Apply to a column containing 25ml Glutathione Sepharose 4 Fast Flow
resin. The injection volumes should be run at a flow rate of 0.1ml/min and
the buffers are run at 4ml/min. Table 10 shows the program guidelines of
the column.
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Table 10 – GST column (post-cleave) program guidelines
Step
Equilibrate Inject/flowWash
Elute
Reequilibrate
through
Volume
2.5 CV*
50ml
3.5 CV* 2.5 CV*
1.25 CV*
Buffer
Lysis
Lysis
Lysis
Elution
Lysis
*The column volume (CV) is 25ml Glutathione Sepharose 4 Fast Flow resin that is used.


Analyze fractions of peaks seen on the chromatogram using PAGE and
combine the fractions containing the protein



Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a final volume of ~10-14ml (make sure not to exceed
100uM protein concentration of the protein will precipitate)



For Mdm2/MdmX, load sample onto a GE HiLoad 16/60 Superdex 75
column. The 2ml injection volumes should be run at a flow rate of 1.5ml/min.
Table 11 shows the program guidelines of the column.

Table 11 – GE HiLoad 16/60 Superdex 75 column program guidelines
Step
Equilibrate Inject
Elute
Reequilibrate Inject
Elute
Volume
1.25 CV*
2ml
1.5 CV*
0.25 CV*
2ml
1.5CV
*The column volume (CV) is 30mL of GE HiLoad 16/60 Superdex 75 column that is used.


For p53ND constructs, after the GST post-cleave column, dialyze the
sample overnight into Anion Exchange Load buffer using 3500Da MWCO
dialysis tubing (FisherBrand)



Apply to a column containing 10ml Anion Exchange column. The injection
volumes should be run at a flow rate of 4ml/min and the buffers are run at
5ml/min. Table 12 shows the program guidelines of the column.
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Table 12 – Anion Exchange column program guidelines
Step
Equilibrate Inject
Wash
Elute
Reequilibrate
Volume
2 CV*
5 CV*
3 CV*
18 CV* gradient, 4 3 CV*
CV*
Buffer
Lysis
Lysis
Lysis
Gradient
10%- Lysis
40%
Elution,
100% Elution
*The column volume (CV) is 10ml Anion Exchange column that is used.


Analyze fractions of peaks seen on the chromatogram using PAGE and
combine the fractions containing the protein



Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a final volume of ~6-10ml (make sure not to exceed
100uM protein concentration of the protein will precipitate)



For p53ND constructs, load sample onto a GE HiLoad 16/60 Superdex 75
column. The 2ml injection volumes should be run at a flow rate of 1.5ml/min.
Table 13 shows the program guidelines of the column

Table 13 – GE HiLoad 16/60 Superdex 75 column program guidelines
Step
Equilibrate Inject
Elute
Reequilibrate Inject
Elute
Volume
1.25 CV*
2ml
1.5 CV*
0.25 CV*
2ml
1.5CV
*The column volume (CV) is 30mL of GE HiLoad 16/60 Superdex 75 column that is used.


Analyze fractions of peaks seen on the chromatogram using SDS-PAGE
and combine those fractions containing the protein



Concentrate combined sample in an Amicon Ultra-15 3K centrifugal filter
device until it reaches a desired concentration that does not exceed 100uM



Dialyze sample in NMR buffer or ITC buffer overnight using 3500Da MWCO
dialysis tubing (FisherBrand)

To prepare 1L of NMR buffer for p53ND constructs:


50mM Sodium Phosphate Monobasic Monohydrate (6.895g)
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50mM NaCl (2.922g)



0.02% Sodium Azide (1mL of 20% stock)



Bring to 2L with ddH2O



pH to 8 and filter sterilize into 1L bottle

To prepare 2L of low ionic strength (85mM) ITC buffer:


10mM Sodium Phosphate Monobasic Monohydrate (13.79g)



150mM NaCl (17.532g)



0.02% Sodium Azide (2mL of 20% stock)



8mM β-mercapthoethanol (1.25ml of 100% stock)



Bring to 2L with ddH2O



pH to 8 and filter sterilize into 2 1L bottles

Finally concentrate to desired NMR or ITC concentration or freeze with 50%
glycerol in -80°C.
Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDSPAGE)
Preparing a 6%-16% gradient gel:
To make 250ml of 4X Lower Gel Buffer:


1.5M Tris Base (45.427g)



0.4% SDS (1g)



Fill to 250mL with ddH2O water



pH 8.8

To make 250ml of 4X Upper Gel Buffer:


0.5M Tris Base (15.142g)
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0.4% SDS (1g)



Fill to 250mL with ddH2O water



pH 6.8

To make Lower gel 6% solution in a 15ml Falcon tube:


1.25ml 4X LOWER gel buffer



2.94ml ddH2O



750μl of 40% Acrylamide



Mix well by pipetting



50μl 10% APS



Mix well by pipetting



5μl TEMED (Add when ready to create gel)



Mix well by pipetting

To make Lower gel 16% solution in a 15ml Falcon tube:


1.25 mL 4X LOWER gel buffer



1.695mL ddH2O



2mL 40% Acrylamide



Mix well by pipetting



50μL 10% APS



Mix well by pipetting



5μL TEMED (Add when ready to create gel)



Mix well by pipetting

To make Upper gel 4% solution in 15ml Falcon tube:


1ml 4X UPPER gel buffer
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2.556mL ddH2O



400μl 40% Acrylamide



Mix well by pipetting



40μl 10% APS



Mix well by pipetting



4μl TEMED (Add when ready to create top layer of gel)



Mix well by pipetting

To prepare gel:


Add 1ml of the 16% LOWER gel to the gel apparatus



Add 1ml of 6% LOWER gel to the tube containing the remaining 16%
LOWER gel and mix by pipetting or inverting, be careful not to create too
many bubbles



Add 1ml of the mixed LOWER gel solution to the gel apparatus



Add 1ml of 6% LOWER gel to the tube containing the remaining 16%
LOWER gel and mix by pipetting or inverting, be careful not to create too
many bubbles



Add 1ml of the mixed LOWER gel solution to the gel apparatus



Add 1ml of 6% LOWER gel to the tube containing the remaining 16%
LOWER gel and mix by pipetting or inverting, be careful not to create too
many bubbles



Add 1ml of the mixed LOWER gel solution to the gel apparatus



Add 200μl of isopropanol to the top of the gel gradient SLOWLY as to no
disturb the gel solution
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Allow the LOWER gel to solidify then pour off the isopropanol.



Add 2-3ml of 4% UPPER gel to the gel apparatus and place comb in the gel
apparatus and wipe off excess UPPER gel that is displaced



Allow the UPPER gel to solidify then remove comb

If making gels for storage wrap in a damp paper towel and store in the fridge for
no longer than a week. When running samples set the power supply to 195 Volts for 45
minutes.

Examples of gels and chromatograms

Figure 21 – p53TAD Nickel Pre-Cleave column chromatogram and SDS-PAGE gel.

Figure 22 – p53TAD SEC column chromatogram and SDS-PAGE gel.
83

Figure 23 – p53ND GST Pre-Cleave column chromatogram and SDS-PAGE gel.

Figure 24 – p53ND GST Post-Cleave column chromatogram and SDS-PAGE gel.

Figure 25 – p53ND Anion Exchange column chromatogram and SDS-PAGE gel.
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Figure 26 – p53ND SEC column chromatogram and SDS-PAGE gel.
Concentration determination
Sample concentrations were determined using the extinction coefficients as
calculated by the ProtParam program available at www.expasy.org (ref#). UV
measurements were obtained using an ND-1000 nanodrop (Thermo Fischer).
Concentration of the sample is calculated from the absorbance value at 280nm using the
Beer’s Law Equation i.e., Absorbance = e*L*c where ‘e’ is the molar extinction coefficient,
‘L’ is the path length of the cell holder and ‘c’ is the concentration of the protein. Table 14
lists the extinction coefficients for the proteins used.
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Table 14 – Protein Extinction Coefficients
Protein

p53TAD WT (residues 1-73)
p53TAD S15D (residues 1-73)
p53TAD S15D/T18E (residues 1-73)
Mdm2 (residues 17–125)
MdmX (residues 23-111)
KIX (residues 586-672)
DBD (residues 94-312)
NDWT (residues 1-312)
T55D-ND (residues 1-312)
NDQS (residues 1-312)

Number of Extinction
Amino Acids Coefficient
(Pre-cleave)
73
11,000
73
11,000
73
11,000
109
53,290
89
50,310
87
13,000
227
61,770
312
78,270
312
78,270
312
78,270

Extinction
Coefficient
(Post-cleave)
11,000
11,000
11,000
10,430
7,350
13,000
18,910
35,410
35,410
35,410

Nuclear Magnetic Resonance
Assignments and Chemical shifts
NMR experiments were performed using uniformly

15N-

and

13C-labeled

samples

at 50μM, at 25°C on a Varian VNMRS 800 MHz spectrometer equipped with a tripleresonance pulse field Z-axis gradient cold probe. To make the amide 1H and 15N as well
as 13Cα, 13Cβ, and 13CO resonance assignments, sensitivity-enhanced 1H–15N HSQC and
three-dimensional HNCACB and HNCO experiments were performed on the uniformly
15N-

and 13C-labeled samples in 90% H2O/8% D2O in NMR buffer for p53ND constructs.

For the HNCO the Varian VNMRS 600 MHz spectrometer with a triple resonance pulse
field Z‐axis gradient cold probe was used. The sweep widths were 9689.9 (t3) Hz × 3770.1
(t2) Hz × 1944.5 (t1) Hz, and complex data points were 1024 (t3) Hz × 64 (t2) Hz × 32 (t1)
Hz. For p53TAD the HSQC and the HNCACB were performed on the 600 MHz
spectrometer. The sweep widths and complex points for the HSQC were 7225.4 (t 2) Hz
× 1500 (t1) Hz and 1024 (t2) Hz × 128 (t1) Hz, respectively. The HNCACB experiment,
data were acquired in the 1H, 13C, and 15N dimensions using 7225.4 (t 3) Hz × 12063.8
(t2) Hz × 1500 (t1) Hz sweep widths and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1) Hz complex
86

data points. For p53TAD S15D the HSQC was performed on the 600 MHz spectrometer
and the HNCACB was performed on the 800 MHz spectrometer. The sweep widths and
complex points for the HSQC were 7266 (t2) Hz × 1943.2 (t1) Hz and 1024 (t2) Hz × 128
(t1) Hz, respectively. The HNCACB experiment, data were acquired in the 1H, 13C, and
15N dimensions using 9689.9 (t3) Hz × 14074.9 (t2) Hz × 1944.3 (t1) Hz sweep widths
and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1) Hz complex data points. For p53TAD S15D/T18E
the HSQC and the HNCACB were performed on the 800 MHz spectrometer. The sweep
widths and complex points for the HSQC were 9689.9 (t 2) Hz × 1944.4 (t1) Hz and 1024
(t2) Hz × 128 (t1) Hz, respectively. The HNCACB experiment, data were acquired in the
1H, 13C, and 15N dimensions using 9689.9 (t3) Hz × 14074.9 (t2) Hz × 1944.3 (t1) Hz
sweep widths and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1) Hz complex data points. For
p53NDWT the HSQC and the HNCACB were performed on the 800 MHz spectrometer.
The sweep widths and complex points for the HSQC were 19,379.8 (t 2) Hz × 2754.5 (t1)
Hz and 1024 (t2) Hz × 128 (t1) Hz, respectively. The HNCACB experiment, data were
acquired in the 1H, 13C, and 15N dimensions using 9689.9 (t3) Hz × 14074.9 (t2) Hz ×
2754.4 (t1) Hz sweep widths and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1) Hz complex data
points. For p53NDWT with conDNA the HSQC and the HNCACB were performed on the
800 MHz spectrometer. The sweep widths and complex points for the HSQC were 9689.9
(t2) Hz × 2754.5 (t1) Hz and 1024 (t2) Hz × 128 (t1) Hz, respectively. The HNCACB
experiment, data were acquired in the 1H, 13C, and 15N dimensions using 9689.9 (t 3) Hz
× 14074.9 (t2) Hz × 2754.4 (t1) Hz sweep widths and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1)
Hz complex data points. For p53T55D-ND the HSQC and the HNCACB were performed
on the 800 MHz spectrometer. The sweep widths and complex points for the HSQC were
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9689.9 (t2) Hz × 2754.5 (t1) Hz and 1024 (t2) Hz × 128 (t1) Hz, respectively. The HNCACB
experiment, data were acquired in the 1H, 13C, and 15N dimensions using 9689.9 (t 3) Hz
× 14074.9 (t2) Hz × 1944.3 (t1) Hz sweep widths and 1024 (t3) Hz × 128 (t2) Hz × 32 (t1)
Hz complex data points. For p53T55D-ND with conDNA the HSQC and the HNCACB
were performed on the 800 MHz spectrometer. The sweep widths and complex points for
the HSQC were 9689.9 (t2) Hz × 2754.5 (t1) Hz and 1024 (t2) Hz × 128 (t1) Hz,
respectively. The HNCACB experiment, data were acquired in the 1H, 13C, and 15N
dimensions using 9689.9 (t3) Hz × 14074.9 (t2) Hz × 2754.4 (t1) Hz sweep widths and
1024 (t3) Hz × 128 (t2) Hz × 32 (t1) Hz complex data points. All NMR spectra were
processed with NMRFxProcessor and analyzed using NMRView J.
Secondary chemical shifts and Random coil chemical shifts
Secondary chemical shift values were calculated by subtracting the residuespecific random coil chemical shifts in the prediction of temperature, neighbor and pHcorrected chemical shifts for intrinsically disordered proteins (POTENCI) from the
measured chemical shifts. Secondary structure populations were calculated with δ2D
using the measured proton, nitrogen, and α, β, and carbonyl carbon chemical shifts. The
overall helicity was calculated as the mean of the per residue δ2D helical population
estimates.
Isothermal Titration Calorimetry
Testing
The p53TAD construct ITC experiments were performed using a GE MicroCal VPITC 200 system instrument. All proteins, p53TAD constructs, Mdm2, MdmX, and KIX,
were dialyzed against ITC buffer for p53TAD constructs. Experiments were performed at
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25°C. The typical concentration of p53TAD constructs (syringe) ranged from 50-500μM
and for Mdm2, MdmX and KIX (cell) 5–50μM. Peptide concentrations were determined
by absorbance at 280nm. A typical ITC experiment consisted of 1 injection of 5μl, followed
by 29 injections of 10μl up to a 2.5-fold molar excess of titrant.
The p53ND construct ITC experiments were performed using a GE MicroCal VPITC 200 system instrument. All proteins, p53ND constructs, Mdm2 and MdmX, and DNA
were dialyzed against low ionic strength (85mM) ITC buffer. Experiments were performed
at 25°C. The typical concentration of p53 constructs (syringe) ranged from 10-150μM and
for Mdm2, MdmX and consensus and scramble DNA (cell) 5–150μM. Peptide
concentrations were determined by absorbance at 280nm. A typical ITC experiment
consisted of 1 injection of 5μL, followed by 19 injections of 15μL up to a 2.5-fold molar
excess of titrant. The following double-stranded DNA oligonucleotides were used:
consensus

5′

AGACATGCCTAGGACATGCCT

and

scrambled

5′TGCCGATCAAAACCGATTCG [172].
Analysis
Data were analyzed with the Microcal Origin software (7.0). Data was fit using a
nonlinear least square curve-fitting algorithm yielding the stoichiometry, enthalpy, and
affinity constants reported for a single binding site. Averages and standard deviations
from three different ITC experiments are shown. Integrated ITC data were fit with singlesite binding models and the stoichiometry ranged from 0.8 to 2. Errors in K d were
calculated from triplicate measurements.
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Appendix A – Chemical shifts
Table 1A – Human p53 Wild Type
Residue
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

AA
M
E
E
P
Q
S
D
P
S
V
E
P
P
L
S
Q
E
T
F
S
D
L
W
K
L
L
P
E
N
N
V
L
S
P

CA shift
55.5549
56.1329
54.2873
63.1199
55.5666
58.1317
52.1294
63.6422
58.9036
61.8362
54.1899
0.0000
62.7182
55.3225
58.0781
55.9466
56.9176
61.9389
58.0296
58.5535
54.8357
56.4631
57.6586
56.8525
54.8878
53.0063
63.6032
57.0527
53.1270
53.3153
62.4529
54.9271
56.1472
62.9133

CB
32.8283
30.5079
29.9025
32.1065
29.8545
63.9449
41.2609
32.1236
63.7779
32.8747
29.7722
0.0000
31.9914
42.4125
63.7501
29.5310
30.8347
69.7908
39.3997
63.7912
40.7647
41.8072
28.9451
32.8760
42.2861
41.5285
31.9833
29.8791
38.9596
39.0797
32.6242
42.3621
63.3320
32.1037

CO shift
175.8920
176.0453
0.0000
176.8751
175.9810
173.7434
0.0000
177.0966
174.5165
175.7947
0.0000
0.0000
176.9181
177.5845
174.5974
176.0104
176.5730
174.3486
175.8600
174.4514
176.8248
177.9919
176.6936
176.1503
177.0305
0.0000
177.4341
176.3449
174.7611
174.8766
176.0100
177.0500
0.0000
176.7157

H Shift
8.4050
8.3590
8.3760
0.0000
8.5180
8.3390
8.3920
0.0000
8.4890
7.8290
8.2970
0.0000
0.0000
8.3030
8.2890
8.4560
8.4370
8.0680
8.2000
8.0640
8.2400
7.9090
7.8160
7.5510
7.7900
7.8810
0.0000
8.6660
8.2490
8.2520
7.9950
8.2470
8.1810
0.0000

N shift
121.4550
122.0190
123.4590
0.0000
120.9510
117.6980
123.6550
0.0000
116.0160
121.0680
126.1130
0.0000
0.0000
122.4360
116.6600
122.4920
121.9240
114.8930
122.2970
116.7370
122.1210
121.1440
119.3610
120.4940
120.7780
123.6980
0.0000
119.8080
118.8430
119.5640
120.1720
125.5200
118.0820
0.0000
100

Table 1A – Human p53 Wild Type (Continued)
35
L
53.1110 41.6515
0.0000
36
P
62.9888 32.0416 177.0251
37
S
58.4488 63.7418 174.6916
38
Q
55.8041 29.6244 175.5471
39
A
52.3593 19.3351 177.8114
40
M
55.5628 32.9049 176.2111
41
D
54.7256 41.1854 176.1620
42
D
54.7016 41.0435 176.3868
43
L
55.4983 42.2339 177.3530
44
M
55.2107 32.4942 175.8877
45
L
54.9340 42.6288 177.0532
46
S
56.0322 63.4948
0.0000
47
P
63.7181 32.0723 176.9795
48
D
54.8233 41.1136 176.2168
49
D
54.6058 41.1968 176.3324
50
I
61.5962 38.8230 176.4156
51
E
56.9733 29.9328 176.5569
52
Q
55.8450 29.5814 175.4430
53
W
57.1601 29.7164 175.6880
54
F
57.4842 39.8114 175.3456
55
T
61.4502 69.9034 173.7619
56
E
56.1628 30.6199 175.7194
57
D
52.3353 41.1181
0.0000
58
P
63.2741 32.2276 177.3178
59
G
44.5121 0.0000
0.0000
60
P
63.3628 32.1500 177.0459
61
D
54.4774 41.0237 176.1261
62
E
56.0845 30.6590 175.7700
63
A
50.6220 18.0453
0.0000
64
P
62.9293 32.0587 176.0104
65
R
55.8240 30.6872 176.2645
66
M
53.1630 32.3271
0.0000
67
P
63.1438 32.0490 176.8751
68
E
56.4809 30.2332 176.1276
69
A
52.1209 19.4111 176.9439
70
A
50.3454 18.1255
0.0000
71
P
62.9539 32.1336 176.6934
72
R
56.0627 30.7927 175.5250
73
V
63.4363 33.3602
0.0000

8.2640
0.0000
8.3000
8.3400
8.2730
8.2930
8.2180
8.2030
8.0440
8.2130
8.0470
8.4830
0.0000
8.1780
8.0590
7.8120
8.3030
8.1030
7.9380
7.9400
7.9510
8.2630
8.4000
0.0000
8.3640
0.0000
8.4080
8.0740
8.2270
0.0000
8.4210
8.4400
0.0000
8.5010
8.2640
8.1800
0.0000
8.4420
7.7080

123.7120
0.0000
115.6800
122.2140
125.2000
119.5410
121.0120
120.1970
121.7310
120.3470
123.1500
118.4350
0.0000
118.8120
120.2100
120.1620
123.7100
120.3870
121.4910
121.4910
116.2660
123.3580
123.3850
0.0000
109.3270
0.0000
119.8830
120.8390
126.5980
0.0000
121.8890
123.2890
0.0000
121.2070
125.3780
124.8270
0.0000
122.4720
125.5260
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Table 1B – p53 S15D
Residue
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

AA
M
E
E
P
Q
S
D
P
S
V
E
P
P
L
D
Q
E
T
F
S
D
L
W
K
L
L
P
E
N
N
V
L
S
P
L
P
S
Q
A

CA shift
55.6317
56.3124
54.3240
63.0]254
55.5683
58.2754
52.3624
63.2222
58.9853
61.8579
54.1845
0.0000
62.6227
55.3491
54.2322
56.2004
57.2989
62.1783
58.1232
58.7939
54.9757
56.5411
57.9051
56.8990
54.8114
53.1322
63.6307
57.0817
53.2458
53.3321
62.5887
54.9579
56.2565
62.8357
53.2311
63.1014
58.5003
55.8582
52.2456

CB
32.8530
30.6644
30.1297
32.0597
29.6354
64.0893
41.2986
32.2351
63.8122
32.8831
29.6852
0.0000
32.1412
42.6884
41.0524
29.6557
30.1847
69.7326
39.3800
63.8317
40.7664
41.8248
28.9436
32.7819
42.3063
41.4376
31.9960
29.8770
39.0609
39.1180
32.6221
42.3729
63.2711
32.1011
41.5684
32.1475
63.8341
29.7038
19.1784

CO shift
175.9221
176.1178
0.0000
176.9554
176.0171
175.9202
0.0000
177.1384
174.5622
175.8122
0.0000
0.0000
176.9460
177.3523
176.2041
176.2166
176.8222
174.4750
175.9093
174.5242
176.8545
178.0463
176.7392
176.2130
177.0562
0.0000
177.4575
176.3875
174.8292
174.8955
176.0752
177.0554
0.0000
176.7423
0.0000
177.0680
174.7173
175.5405
177.8414

H Shift
8.3819
8.3439
8.3575
8.4759
8.4942
8.3160
8.3768
8.4682
8.4600
7.8265
8.2832
0.0000
8.2903
8.2933
8.3089
8.2303
8.4497
8.0251
8.1524
8.0189
8.2344
7.8790
7.7833
7.5143
7.7646
7.8560
8.6511
8.6426
8.2214
8.2191
7.9729
8.2218
8.1680
8.2515
8.2432
8.2861
8.2860
8.3172
8.2462

N shift
121.6523
122.2042
123.6495
121.0912
121.1277
117.8762
123.7141
116.2152
116.2307
121.2980
126.3405
0.0000
122.7895
122.7971
121.2192
120.7265
122.0345
114.9600
122.3981
116.9350
122.2833
121.2964
119.4899
120.6415
120.8973
123.8893
119.9644
119.9716
119.0291
119.7639
120.3817
125.7496
118.2827
123.9002
123.9011
115.8621
115.8637
122.4035
125.4032
102

Table 1B – p53 S15D (Continued)
40
M
55.5839 32.8940
41
D
54.8536 41.3199
42
D
54.6119 40.9724
43
L
55.5275 42.3984
44
M
55.6008 32.6019
45
L
55.0466 42.7556
46
S
56.1416 63.5888
47
P
63.7780 32.0618
48
D
54.9431 41.1265
49
D
54.6060 41.2433
50
I
61.6119 38.9424
51
E
57.0055 30.0844
52
Q
55.7513 29.6656
53
W
57.0659 29.8527
54
F
57.3451 39.8385
55
T
61.4757 69.9499
56
E
56.1731 30.6699
57
D
52.2444 41.1502
58
P
63.3180 32.3569
59
G
44.6275 0.0000
60
P
63.5046 32.2003
61
D
54.4874 41.0426
62
E
56.1031 30.6886
63
A
50.7412 18.1648
64
P
63.0309 32.2621
65
R
55.8704 30.9769
66
M
53.1953 32.1621
67
P
63.0857 32.1011
68
E
56.7174 30.4539
69
A
52.6805 19.4819
70
A
50.4653 18.1598
71
P
62.9392 32.1553
72
R
56.1010 30.8122
73
V
63.4674 33.4683

176.2490
176.2204
176.4379
177.3941
175.9193
177.0919
0.0000
176.9902
176.2669
176.3793
176.4557
176.5885
175.5834
175.5834
175.3647
173.8174
173.7805
0.0000
177.3644
0.0000
177.1036
176.2251
175.7879
0.0000
176.8134
176.2764
0.0000
176.9158
176.1391
176.9609
0.0000
176.7163
175.5538
175.5538

8.2745
8.1935
8.1769
8.0291
8.1858
8.0348
8.4580
8.1961
8.1536
8.0372
7.7866
8.2822
8.0917
7.9417
7.9168
7.9303
8.2410
8.3760
8.3388
8.3389
8.3874
8.3795
8.0461
8.2138
8.4013
8.3990
8.4283
8.4914
8.4782
8.2473
8.1536
8.4202
8.4176
7.6823

119.7301
121.1981
120.3699
121.8829
120.5140
123.3578
118.6195
118.9957
119.0033
120.3712
120.3351
123.9294
120.5804
121.6536
121.6812
116.4534
123.5358
123.7159
109.4867
109.4813
120.0506
120.0538
120.9836
126.7629
122.0626
122.0546
123.4799
121.3346
121.3757
125.5366
125.0023
122.6271
122.6256
125.6816

CO shift
176.5813
176.0278
0.0000

H Shift
8.4053
8.3573
8.3810

N shift
121.6560
121.8903
123.6270

Table 1C – p53 S15D/T18E
Residue
1
2
3

AA
M
E
E

CA shift
55.5759
56.9143
54.3624

CB
32.8942
30.3367
29.8946
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Table 1C – p53 S15D/T18E (Continued)
4
P
63.2092 32.1621
5
Q
55.6055 29.7775
6
S
58.2137 64.0286
7
D
52.3141 41.2364
8
P
63.1625 32.1954
9
S
58.9220 63.8532
10
V
61.8930 32.9347
11
E
54.2153 29.8140
12
P
0.0000
0.0000
13
P
62.6451 32.0700
14
L
55.2673 42.6387
15
D
54.3282 41.1263
16
Q
55.9667 29.7780
17
E
57.0326 30.5836
18
E
56.9301 30.2227
19
F
57.7728 39.3666
20
S
58.7541 63.9510
21
D
54.8938 40.7752
22
L
56.6247 41.8402
23
W
57.7376 28.9727
24
K
56.9792 32.9237
25
L
54.9296 42.3376
26
L
53.0833 41.5550
27
P
63.6788 32.0330
28
E
57.1234 29.9175
29
N
53.1784 39.0220
30
N
53.3626 39.1594
31
V
62.5412 32.6703
32
L
54.9798 42.4052
33
S
56.2147 63.3950
34
P
62.9634 32.1512
35
L
53.1828 41.7080
36
P
63.1295 32.0889
37
S
58.5153 63.7599
38
Q
55.8474 29.6418
39
A
52.2397 19.4542
40
M
55.6439 32.9410
41
D
54.7918 41.2685
42
D
54.7263 41.1094
43
L
55.5401 42.2717

176.9054
176.0111
173.7677
0.0000
177.1259
174.5537
175.7988
0.0000
0.0000
176.9227
177.3211
177.3903
176.0484
175.8992
176.3155
175.8913
174.6163
176.8904
178.0820
176.7851
176.2310
177.0612
0.0000
177.4574
176.3876
174.8122
174.8802
176.0746
177.0488
0.0000
176.7336
0.0000
177.0582
176.5813
175.4731
177.8320
176.2471
176.1961
176.4347
176.1961

8.5079
8.5236
8.3477
8.4058
8.4848
8.4876
7.8566
8.3116
0.0000
8.3108
8.3109
8.3528
8.2377
8.4439
8.3379
8.1571
8.0232
8.3206
7.9088
7.8094
7.5378
7.7797
7.8776
8.6836
8.6836
8.2496
8.2492
8.0054
8.2591
8.1973
8.2782
8.2782
8.3120
8.3114
8.3496
8.2702
8.3018
8.2243
8.2067
8.0268

121.3330
121.1393
117.8835
123.7205
116.2152
116.2493
121.3188
126.3514
0.0000
122.8046
122.8138
121.2442
120.5328
122.5301
121.6576
120.7913
117.0966
122.2908
121.2736
119.4128
120.6317
120.8537
123.9104
119.9638
119.9753
119.0426
119.7817
120.4195
125.7796
118.3095
123.9259
123.9193
115.8882
115.8743
122.4117
125.5554
119.7407
121.2161
120.3840
121.9045
104

Table 1C – p53 S15D/T18E (Continued)
44
M
55.4574 32.5493
45
L
54.9907 42.6903
46
S
56.0899 63.5294
47
P
63.7990 32.1105
48
D
54.8901 41.1863
49
D
54.6444 41.2831
50
I
61.6508 38.8872
51
E
57.0440 30.0383
52
Q
55.8800 29.6122
53
W
57.1457 29.8022
54
F
56.9800 39.8785
55
T
61.5081 69.9886
56
E
56.2116 30.7088
57
D
52.3440 41.1546
58
P
63.3500 32.3173
59
G
44.5668 0.0000
60
P
63.4361 32.2378
61
D
54.5390 41.0833
62
E
56.1432 30.7340
63
A
50.6853 18.1082
64
P
62.9652 32.1125
65
R
55.8119 31.0080
66
M
53.2411 32.4045
67
P
63.1348 32.1111
68
E
56.5725 30.4053
69
A
52.4789 19.2970
70
A
50.4086 18.2132
71
P
62.9724 32.1772
72
R
56.0754 30.5836
73
V
63.4998 33.4098

175.8948
177.0836
0.0000
176.9810
176.2565
176.3542
176.4503
176.5611
175.5687
175.5687
175.3624
173.8034
173.7677
0.0000
177.3464
0.0000
177.1033
176.1558
175.7813
0.0000
176.7963
176.2755
0.0000
176.8752
175.9484
176.9558
0.0000
176.6941
175.5500
0.0000

8.2183
8.0556
8.4884
8.1827
8.1830
8.0614
7.8164
8.3121
8.1107
7.9458
7.9171
7.9570
8.2690
8.4066
8.3677
8.3678
8.4107
8.4098
8.0778
8.2369
8.4271
8.4274
8.4484
8.4850
8.5042
8.2464
8.1882
8.4465
8.4460
7.7120

120.5232
123.3573
118.6302
119.0138
119.0135
120.3773
120.3435
123.9353
120.5886
121.6931
121.7278
116.4460
123.5427
123.7159
109.4829
109.4862
120.0724
120.0678
120.9956
126.7709
122.0722
122.0635
123.4874
121.4702
121.3860
125.5947
125.0054
122.6306
122.6031
125.6873

CO shift
176.0050
176.1178
0.0000
176.9083
176.0005
173.7503
0.0000

H Shift
8.2932
8.2932
8.3498
8.5239
8.5254
8.3496
8.4037

N shift
121.8182
121.8182
123.5811
121.2200
121.2528
117.9274
123.8319

Table 1D – p53 T55D-ND
Residue
1
2
3
4
5
6
7

AA
M
E
E
P
Q
S
D

CA
55.4517
56.3875
54.2631
63.1631
55.5455
58.1632
52.1602

CB
32.7861
30.4846
29.8224
32.0694
29.8026
63.9651
41.2686
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Table 1D – p53 T55D-ND (Continued)
63.1067 63.7744
8
P
58.9151 32.0991
9
S
61.8308 32.8744
10
V
54.1593 29.7686
11
E
0.0000
0.0000
12
P
62.6923 31.9915
13
P
55.2642 42.4140
14
L
58.0875 63.7757
15
S
55.5703 29.5151
16
Q
56.9282 30.1763
17
E
61.9947 69.7958
18
T
57.9948 39.4026
19
F
58.6935 63.7750
20
S
54.8460 40.7541
21
D
56.5207 41.8092
22
L
57.7139 28.9263
23
W
56.8795 32.8641
24
K
54.8951 42.2994
25
L
53.0168 41.5200
26
L
63.6478 31.9767
27
P
57.0687 29.8365
28
E
53.3382 39.0861
29
N
53.3612 39.1175
30
N
62.4952 32.5907
31
V
54.9439 42.3514
32
L
56.1395 63.3798
33
S
62.9403 32.0740
34
P
53.0983 41.6808
35
L
63.0887 32.0233
36
P
58.5203 63.7339
37
S
55.8769 29.6167
38
Q
52.6381 19.2319
39
A
55.6146 32.8667
40
M
54.7939 41.2005
41
D
54.7599 41.0293
42
D
55.5275 42.2176
43
L
55.7924 32.5130
44
M
54.9083 42.6674
45
L
56.0603 63.5421
46
S
63.9587 32.0358
47
P
54.8729 41.1303
48
D
54.6756 41.2441
49
D

177.1218
174.5291
175.7957
0.0000
0.0000
176.9129
177.6257
0.0000
174.6754
176.5902
174.3922
175.8928
174.4911
176.8545
178.0132
176.7392
176.1467
177.0328
0.0000
177.4575
176.3378
174.7961
174.8789
176.0997
177.0720
0.0000
176.6926
0.0000
177.0680
174.7339
175.5902
177.8414
176.2656
176.2204
176.4361
177.3941
175.9028
177.0257
0.0000
176.9736
176.2338
176.3414

8.4934
8.4924
7.8345
8.3037
0.0000
8.3154
8.3154
8.3009
8.4586
8.0739
8.0834
8.2162
8.0764
8.2445
7.9131
7.8210
7.5520
7.7961
7.8775
8.6755
8.6759
8.2507
7.9953
7.9963
8.2489
8.1812
8.2657
8.2667
8.3052
8.3054
8.3511
8.2627
8.2837
8.2175
8.1984
8.0465
8.1928
8.0436
8.4901
8.1791
8.1821
8.0407

116.2845
116.2361
121.2805
126.3371
0.0000
122.6356
122.6334
116.8773
122.1492
115.0841
115.1243
122.4599
116.8453
122.3319
121.3415
119.5116
120.6033
120.8960
123.8462
119.9918
119.9927
119.6536
120.2934
120.3101
125.5905
118.2264
123.9022
123.8959
115.8557
115.8300
122.4183
125.2154
119.6583
121.1681
120.5382
121.8275
120.3584
123.0987
118.5967
118.6718
118.8234
120.3801
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Table 1D – p53 T55D-ND (Continued)
61.5484 38.7560
50
I
0.0000
0.0000
51
E
0.0000
0.0000
52
Q
0.0000
0.0000
53
W
0.0000
0.0000
54
F
0.0000
0.0000
55
D
56.2738 30.4521
56
E
52.8731 41.6391
57
D
63.2830 32.2518
58
P
44.5270 0.0000
59
G
63.4222 32.1642
60
P
54.5204 41.0166
61
D
56.0812 30.6528
62
E
50.6403 18.0868
63
A
62.9159 32.0552
64
P
56.0802 30.9347
65
R
53.1786 32.3284
66
M
63.1631 32.1159
67
P
56.5531 30.2673
68
E
52.2006 19.3874
69
A
50.2803 18.3030
70
A
62.7443 32.0546
71
P
55.9999 30.9141
72
R
61.7556 33.0281
73
V
50.3374 18.3284
74
A
0.0000
0.0000
75
P
0.0000
0.0000
76
A
0.0000
0.0000
77
P
0.0000
0.0000
78
A
0.0000
0.0000
79
A
62.9309 31.9967
80
P
59.6711 69.7505
81
T
62.9429 32.0551
82
P
52.1501 19.3549
83
A
50.3671 18.2195
84
A
62.6749 32.0710
85
P
50.3119 18.1438
86
A

0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
173.7640
0.0000
177.3772
0.0000
177.0539
176.1146
175.7382
0.0000
176.7803
176.2764
0.0000
176.9324
176.1060
176.9720
0.0000
176.0428
176.2500
175.3162
0.0000
0.0000
0.0000
0.0000
0.0000
0.0000
176.7947
0.0000
176.5149
177.0134
0.0000
176.2629
0.0000

7.7883
0.0000
0.0000
0.0000
0.0000
0.0000
8.3914
8.3908
8.3589
8.3571
8.4098
8.4098
8.0624
8.2205
8.4285
8.4277
8.4243
8.5239
8.5128
8.2359
8.1866
8.4285
8.4318
8.1255
8.3623
0.0000
0.0000
0.0000
0.0000
0.0000
8.2308
8.2321
8.3056
8.3040
8.1508
8.3173
8.3182

120.0346
0.0000
0.0000
0.0000
0.0000
0.0000
125.2787
125.2900
109.3980
109.4295
120.0027
120.0099
120.7982
126.5899
122.0211
122.0497
123.2581
121.2200
121.1395
125.2833
124.8840
122.0497
122.0497
121.8309
129.7156
0.0000
0.0000
0.0000
0.0000
0.0000
117.2088
117.2526
124.6722
124.6594
124.7676
125.9032
125.9082
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